[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 172
1. Girardi S, Gaudy C, Gouvernet J, Teston J, Richard MA, Grob JJ: Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study. Int J Cancer; 2006 May 1;118(9):2276-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study.
  • Most education campaigns for melanoma (MM) detection in the general population have used the "ABCD" algorithm, although recognition of objects in the real life is based on a holistic image recognition rather than on analytic criteria.
  • A prospective 4-arm stratified randomized trial in 255 individuals compared 3 realistic educative interventions by leaflets:.
  • 1) ABCD algorithm ("ABCD"), 2) a set of photographs chosen to stimulate recognition of MM among benign pigmented lesions ("Cog"), 3) photographs + explanations ("Cog-Ex" arm) and 4) no intervention ("NI").
  • In the "ABCD" arm, sensitivity slightly improved (80 to 83.8%, p = 0.04), but specificity dropped from 65.1 to 56.3% (p < 0.001), with no benefit in accuracy as compared to "NI".
  • In "Cog" arm, there was no change in sensitivity, but a strong increase in specificity (65.9 to 81.1%, p < 0.001) and accuracy (42.1 to 53.1%, p < 0.001).
  • Under stress (T2), there was a dramatic loss of specificity and accuracy in "ABCD" arm (65.1 to 44.1%, p < 0.001 and 40.8% to 35.8%, p < or = 0.001) without higher gain in sensitivity, while sensitivity and accuracy increased (p < 0.005) after "Cog" leaflet, without decreasing specificity.
  • [MeSH-major] Cognition. Melanoma / diagnosis. Patient Education as Topic. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16331608.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C: Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol; 2006 Oct;17(10):1592-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
  • BACKGROUND: Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours.
  • The purpose of this study was to test a dose-intensified regimen of temozolomide in melanoma patients with brain metastases in a prospective, open-label, multicentre phase II trial.
  • PATIENTS AND METHODS: Forty-five patients with asymptomatic brain metastases from melanoma were stratified into arm A (no prior chemotherapy; n = 21) and arm B (previous chemotherapy; n = 24).
  • Patients received oral temozolomide either 150 mg/m(2)/day (arm A) or 125 mg/m(2)/day (arm B), days 1-7 and 15-21, every 28 days.
  • RESULTS: Two patients (4.4%) achieved a partial response (PR) in brain metastases (one in each arm), one of them (2.2%) also showing a PR in extracerebral disease.
  • An additional five patients (11.1%; two in arm A, three in arm B) showed disease stabilisation (SD) in brain and other sites.
  • Median survival time from therapy onset was 3.5 months (range 0.7-8.3; arm B) and 4.3 months (range 1.6-11.8; arm A), P = 0.43.
  • CONCLUSIONS: Oral administration of temozolomide given bi-weekly is well-tolerated in melanoma patients with cerebral involvement.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005632.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Kroon HM, Lin DY, Kam PC, Thompson JF: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg; 2009 Jun;249(6):1008-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
  • INTRODUCTION: The treatment of elderly patients with advanced metastatic melanoma confined to a limb remains controversial.
  • METHODS: From our prospective database 185 patients with advanced metastatic melanoma of the limb treated with a single ILI between 1992 and 2007 were identified.
  • CONCLUSIONS: Elderly patients with advanced metastatic melanoma of the limb experience the same or lower toxicity after ILI compared with younger patients while response rates, limb recurrence free interval, survival, and morbidity are similar.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Arm. Cohort Studies. Female. Humans. Hyperthermia, Induced. Infusions, Intra-Arterial. Leg. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474677.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Haenssle HA, Kaune KM, Buhl T, Thoms KM, Padeken M, Mitteldorf C, Emmert S: Large speckled lentiginous naevus superimposed with Spitz naevi: sequential digital dermoscopy may lead to unnecessary excisions triggered by dynamic changes. Clin Exp Dermatol; 2009 Mar;34(2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 14-year-old girl with a large speckled lentiginous naevus (SLN) on her left arm and shoulder.
  • As the occurrence of melanoma within SLN has been described previously, long-term follow-up of atypical lesions by digital dermoscopy was started at the age of 4 years.
  • No melanoma has so far been detected.
  • In order to avoid unnecessary excisions triggered by subtle dynamic changes, a standard approach with overview images, conventional dermoscopy and early excision of lesions that are rated as suspicious for melanoma by established algorithms may be recommended.
  • [MeSH-major] Dermoscopy / methods. Melanoma / pathology. Nevus, Epithelioid and Spindle Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2009 Mar;34(2):133-5 [19040513.001]
  • (PMID = 19040514.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE: In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol; 2006 Dec;155(6):1287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ photoimmunotherapy: a tumour-directed treatment for melanoma.
  • We report a new immunological treatment for advanced cutaneous melanoma which combines laser stimulation with topical application of a toll-like receptor agonist.
  • This treatment, in situ photoimmunotherapy (ISPI), provides an alternative to traditional therapies for melanoma patients with cutaneous metastases.
  • Two patients with late-stage melanoma were treated with ISPI.
  • Patient 1 had the primary tumour and local metastases on the left arm, as well as metastatic tumours in the lungs [American Joint Committee on Cancer (AJCC) stage IV].
  • Patient 2 had a head and neck melanoma with multiple local metastases (AJCC stage IIIC), which had failed repeated attempts at surgical resection and high-dose radiation therapy.
  • These two cases demonstrate that ISPI can clear local tumour and trigger beneficial systemic responses, with a side-effect profile that compares favourably with other treatments for advanced melanoma.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Melanoma / therapy. Photochemotherapy / methods. Skin Neoplasms / therapy. Toll-Like Receptors / agonists

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107404.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016478
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Toll-Like Receptors; 99011-02-6 / imiquimod
  •  go-up   go-down


6. Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S: Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer; 2008 Jan 1;112(1):193-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of metastasis included the abdominal wall (25 patients), back, including scapular region (20 patients), thigh (17 patients), chest wall (15 patients), arm (15 patients), shoulder (11 patients), buttock (5 patients), perineum (3 patients), leg (2 patients), foot (1 patient), umbilical area (1 patient), ankle (1 patient), scalp (1 patient), and elbow (1 patient).
  • The histologic classification of the tumors included carcinoma (83 patients), malignant melanoma (20 patients), sarcoma and carcinosarcoma (9 patients), malignant mixed Mullerian tumor (2 patients), seminoma (1 patient), malignant teratoma (1 patient), malignant gastrointestinal stromal tumor (1 patient), and neuroblastoma (1 patient).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Melanoma / pathology. Melanoma / secondary. Middle Aged. Sarcoma / pathology. Sarcoma / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 18040999.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Geller AC, Emmons KM, Brooks DR, Powers C, Zhang Z, Koh HK, Heeren T, Sober AJ, Li F, Gilchrest BA: A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer; 2006 Aug 15;107(4):806-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial to improve early detection and prevention practices among siblings of melanoma patients.
  • BACKGROUND: Identifying high-risk individuals for melanoma education and risk reduction may be a viable strategy to curb the incidence of melanoma, which has risen precipitously in the past 50 years.
  • The first-degree relatives of melanoma patients represent a risk group who may experience a 'teachable moment' for enhanced education and risk reduction.
  • METHODS: We report a randomized trial testing an intervention that provided personalized telephone counseling and individually tailored materials to siblings of recently-diagnosed melanoma patients.
  • Families in the usual care arm received the suggestion from the physician that patients diagnosed with melanoma notify the family members about their diagnosis and encourage the family members to be screened.
  • CONCLUSIONS: This study is the one of the first, to our knowledge, to address skin cancer risk-reduction strategies in a sample of individuals who have a recent family diagnosis of melanoma.
  • Diagnosis of melanoma in a family member provides an important opportunity to intervene with others in that family.
  • The components of the intervention may provide a useful foundation for future efforts to target the more than half million siblings at risk for melanoma, a lethal but preventable disease.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Melanoma / diagnosis. Melanoma / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832795.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA76333
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


8. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol; 2008 May 1;26(13):2178-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
  • PURPOSE: This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.
  • PATIENTS AND METHODS: This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naive patients with stage III (unresectable) or IV melanoma.
  • RESULTS: Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068).
  • There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm.
  • CONCLUSION: Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


9. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A: Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol; 2008 Jun;19(6):1195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
  • BACKGROUND: More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent disease within the first 3 years after surgery.
  • PATIENTS AND METHODS: A total of 444 patients from 42 centers of the German Dermatologic Cooperative Oncology Group who had received a complete lymph node dissection for pathologically proven regional node involvement were randomized to receive either 3 MU s.c. of IFNalpha2a three times a week for 2 years (Arm A) or combined treatment with same doses of IFNalpha2a plus DTIC 850 mg/m(2) every 4-8 weeks for 2 years (Arm B) or to observation alone (Arm C).
  • No improvement of survival was found for the combined treatment Arm B with 45% survival rate (B versus C, P = 0.76).
  • Similarly, DFS rates showed significant benefit for Arm A, and not for Arm B.
  • Multivariate Cox model confirmed that Arm A has an impact on OS (P = 0.005) but not Arm B (P = 0.34).
  • CONCLUSIONS: 3 MU interferon alpha2a given s.c. three times a week for 2 years significantly improved OS and DFS in patients with melanoma that had spread to the regional lymph nodes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281266.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


10. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother; 2008 Oct;31(8):781-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
  • Here, we report the results of a pilot trial designed to study the immunogenicity of the analog peptide NY-ESO-1 157-165V in combination with CpG 7909/PF3512676 and Montanide ISA 720 in patients with stage III/IV NY-ESO-1-expressing melanoma.
  • Eight patients were immunized either with Montanide and CpG (arm 1, 3 patients); Montanide and peptide NY-ESO-1 157-165V (arm 2, 2 patients); or with Montanide, CpG, and peptide NY-ESO-1 157-165V (arm 3, 3 patients).
  • Only the 3 patients immunized with Montanide, CpG, and peptide NY-ESO-1 157-165V in arm 3 developed a rapid increase of effector-memory NY-ESO-1-specific CD8+ T cells, detectable ex vivo.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1757-64 [10359579.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):472-7 [15534491.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):739-46 [15696196.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1243-55 [15837811.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):252-7 [15838382.001]
  • [Cites] PLoS Med. 2004 Nov;1(2):e28 [15578105.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1912-6 [16488988.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s [16609053.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):317-27 [16482562.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 [17517626.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2042-8 [17640060.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):948-55 [10878370.001]
  • [Cites] Int Immunol. 1999 Dec;11(12):1971-80 [10590263.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s [11300471.001]
  • [Cites] Annu Rev Immunol. 2002;20:709-60 [11861616.001]
  • [Cites] Nat Med. 2002 Apr;8(4):379-85 [11927944.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):1822-9 [12574347.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Eur J Immunol. 1992 May;22(5):1261-9 [1533591.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):63-7 [8752841.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2539-48 [8805655.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • (PMID = 18779741.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112198; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCI NIH HHS / CA / R01 CA090360; United States / NCI NIH HHS / CA / R01 CA090360-05S1; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCI NIH HHS / CA / R01 CA112198-01; United States / NCI NIH HHS / CA / P50 CA121973; United States / NCI NIH HHS / CA / R01 CA112198-02; United States / NCI NIH HHS / CA / R01 CA090360-04; United States / NCI NIH HHS / CA / R01 CA090360-01A2; United States / NCRR NIH HHS / RR / M01 RR000056-441011; United States / NCI NIH HHS / CA / R01 CA090360-02; United States / NCI NIH HHS / CA / R01 CA112198-04; United States / NCI NIH HHS / CA / R01 CA112198-03; United States / NCI NIH HHS / CA / R01 CA090360-05; United States / NCI NIH HHS / CA / R01 CA090360-03; United States / NCI NIH HHS / CA / CA90360; United States / NCRR NIH HHS / RR / M01 RR000056-36; United States / NCRR NIH HHS / RR / UL1 RR024153-01; United States / NCI NIH HHS / CA / R01 CA112198
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Neoplasm Proteins; 0 / Oleic Acids; 0 / Oligodeoxyribonucleotides; 0 / Peptide Fragments; 0 / ProMune; 0 / peptide NY-ESO-1 157-165; 25339-93-9 / mannide monooleate; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ NIHMS84664; NLM/ PMC3901357
  •  go-up   go-down


11. Nan H, Qureshi AA, Hunter DJ, Han J: A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control; 2009 Mar;20(2):171-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the effect of MDM2 SNP309 and its interaction with the p53 Arg72Pro polymorphism on pigmentary phenotypes and skin cancer risk in a nested case-control study within the Nurses' Health Study (NHS) among 219 melanoma cases, 286 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 873 controls, and among controls from other studies.
  • We found that the G allele of the MDM2 SNP309 was inversely associated with the presence/absence of moles on the arm among 3,207 women pooled from controls of three nested case-control studies within the NHS.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):72-7 [10625176.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1605-9 [10789732.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2000 Oct;16(5):195-201 [11068857.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1550-1 [11115171.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):513-9 [12394194.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):311-5 [12893080.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):760-2 [15373782.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):724-33 [6358278.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):857-60 [8479525.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2258-62 [8182158.001]
  • [Cites] BMJ. 1995 Apr 8;310(6984):912-6 [7719184.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2445-9 [8570197.001]
  • [Cites] Nat Med. 1996 Aug;2(8):912-7 [8705862.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):245-51 [9119548.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1123-8 [9070662.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):410-4 [9351343.001]
  • [Cites] Oncogene. 1998 Nov 12;17(19):2543-7 [9824166.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1092-100 [9891044.001]
  • [Cites] Oncogene. 1999 Feb 18;18(7):1419-34 [10050879.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Feb;5(1):3-8 [15720184.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Aug;37(8):1547-53 [15896663.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1252-8 [16354196.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2608-15 [16510579.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):195-7 [16239061.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4867-71 [16914573.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1976-84 [16721784.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1514-21 [16943234.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):660-4 [17123590.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):621-5 [17387621.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):375-7 [17553029.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2262-7 [17827408.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):314-21 [18510673.001]
  • (PMID = 18814047.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122838-01A2; United States / NCI NIH HHS / CA / R01 CA122838; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / R03 CA128080; United States / NCI NIH HHS / CA / CA122838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS70183; NLM/ PMC2631619
  •  go-up   go-down


12. Boasberg P, Hamid O, O'Day S: Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol; 2010 Oct;37(5):440-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma is rising faster in incidence than any other malignancy.
  • A randomized trial has documented a survival benefit when ipilimumab was compared to a gp-100 vaccine only arm.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 21074058.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ipilimumab; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


13. Mensink HW, Vaarwater J, Kiliç E, Naus NC, Mooy N, Luyten G, Brüggenwirth HT, Paridaens D, de Klein A: Chromosome 3 intratumor heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci; 2009 Feb;50(2):500-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 3 intratumor heterogeneity in uveal melanoma.
  • PURPOSE: To investigate the presence of focal or diffuse heterogeneity of monosomy 3 in uveal melanoma, by using fluorescence in situ hybridization (FISH).
  • Tumors with monosomy 3 were suspected to be heterogeneous if there were low percentages of monosomy 3, triploid clones, inconsistencies between FISH on centromere 3 and the long arm of chromosome 3, or discrepancies between fine-needle-aspiration biopsies (FNABs) and the main tumor.
  • In general, tumor biopsies in uveal melanoma provide an accurate prediction of the patient's prognosis.
  • [MeSH-major] Choroid Neoplasms / genetics. Chromosomes, Human, Pair 3 / genetics. Genetic Heterogeneity. Melanoma / genetics. Monosomy / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824727.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U: Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer; 2006 Nov;42(17):2991-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
  • BACKGROUND: Chemoimmunotherapy for patients with metastatic melanoma is associated with high toxicity, and only a subset of patients will benefit.
  • PATIENTS AND METHODS: Patients with metastatic melanoma were randomised to either receive chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha and interleukin-2 (arm A) or initial treatment with two cycles of dacarbazine monotherapy followed irrespective of response by the same 4-drug regimen of chemoimmunotherapy (arm B).
  • Disease stabilisation (complete/partial response or stable disease) was achieved in 19 patients (42.2%) in arm A and 9 patients (20.5%) in arm B.
  • In arm B 32 of the 44 patients continued chemoimmunotherapy after two cycles of dacarbazine.
  • Of 20 patients with progressive disease (PD) after two cycles of dacarbazine in arm B, only 2 patients achieved an objective response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / therapeutic use. Immunotherapy / methods. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023156.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD: Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res; 2010 Aug 01;16(15):4057-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
  • EXPERIMENTAL DESIGN: Human leukocyte antigen (HLA)-A*0201(+) disease-free melanoma patients were randomized to the PMED or i.m. arm, receiving eight vaccinations over 4 months.
  • RESULTS: Twenty-seven patients with stage IIB-IV melanoma were analyzable for immune response.
  • Overall, vaccination induced a response in 30% of patients, which was not significantly associated with study arm or clinical outcome.
  • [MeSH-major] Biolistics. Cancer Vaccines / administration & dosage. Cancer Vaccines / immunology. Melanoma / therapy. Membrane Glycoproteins / administration & dosage
  • [MeSH-minor] Administration, Intranasal. Adult. Aged. Animals. Antigens, Heterophile / administration & dosage. Antigens, Heterophile / adverse effects. CD8-Positive T-Lymphocytes / immunology. DNA / administration & dosage. DNA / adverse effects. DNA / immunology. Female. HLA-A Antigens. HLA-A2 Antigen. Humans. Kaplan-Meier Estimate. Male. Mice. Middle Aged. Neoplasm Staging. Peptides. Pilot Projects. Vaccines, DNA / administration & dosage. Vaccines, DNA / adverse effects. Vaccines, DNA / immunology. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7412-20 [19934295.001]
  • [Cites] Clin Plast Surg. 2010 Jan;37(1):127-46 [19914464.001]
  • [Cites] Cytokines Cell Mol Ther. 1999 Dec;5(4):217-25 [10850386.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):137-43 [11796010.001]
  • [Cites] Vaccine. 2003 Sep 8;21(25-26):4036-42 [12922140.001]
  • [Cites] Nature. 1992 Mar 12;356(6365):152-4 [1545867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4455-9 [8506285.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1553-61 [9802967.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):95-106 [17251916.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):540-9 [17255276.001]
  • [Cites] Int Immunol. 2007 Oct;19(10):1223-34 [17898045.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5950-6 [19018089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1075-81 [19139427.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2130-9 [19276258.001]
  • [Cites] Cancer Immun. 2009;9:5 [19496531.001]
  • [Cites] Vaccine. 2009 Sep 4;27(40):5450-9 [19622402.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5591-8 [19671877.001]
  • [Cites] Clin Cancer Res. 2009 Nov 15;15(22):6881-90 [19903784.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • (PMID = 20647477.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCI NIH HHS / CA / P01CA33049
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Heterophile; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide; 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS215758; NLM/ PMC4241567
  •  go-up   go-down


16. Ives NJ, Stowe RL, Lorigan P, Wheatley K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol; 2007 Dec 1;25(34):5426-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
  • PURPOSE: To assess the effect of adding interferon-alpha (IFN) +/- interleukin-2 (IL-2) to chemotherapy in patients with metastatic melanoma.
  • METHODS A published data meta-analysis of trials of biochemotherapy versus chemotherapy in patients with metastatic melanoma was undertaken.
  • The only subgroup analysis performed was by type of immunotherapy, with trials divided according to whether IFN only or IFN and IL-2 were administered in the biochemotherapy arm.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048825.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


17. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E: Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res; 2005 Dec 1;65(23):11156-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using melanoma, carcinoma, and lymphoma models, we show that tumor growth was inhibited in tumor-bearing mice vaccinated against FAP and that the magnitude of the antitumor response was comparable to that of vaccination against tumor cell-expressed antigens.
  • The antitumor response could be further enhanced by augmenting the CD4+ T-cell arm of the anti-FAP immune response, achieved by using a lysosomal targeting sequence to redirect the translated FAP product into the class II presentation pathway, or by covaccination against FAP and a tumor cell-expressed antigen, tyrosinase-related protein 2.
  • [MeSH-minor] Animals. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Growth Processes / immunology. Dendritic Cells / immunology. Fibroblasts / immunology. Fibroblasts / pathology. Gelatinases. Immunotherapy. Immunotherapy, Adoptive / methods. Lysosome-Associated Membrane Glycoproteins / immunology. Mammary Neoplasms, Experimental / genetics. Mammary Neoplasms, Experimental / immunology. Mammary Neoplasms, Experimental / pathology. Mammary Neoplasms, Experimental / therapy. Melanoma, Experimental / genetics. Melanoma, Experimental / immunology. Melanoma, Experimental / pathology. Melanoma, Experimental / therapy. Membrane Proteins. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Thymoma / genetics. Thymoma / immunology. Thymoma / pathology. Thymoma / therapy. Transfection

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322266.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA 89536; United States / NCI NIH HHS / CA / 1R01 CA 98637
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


18. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE: Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol; 2007 May 20;25(15):2078-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
  • PURPOSE: To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b.
  • PATIENTS AND METHODS: An Ad Hoc Melanoma Working Group of 25 investigators treated 604 patients from April 1997 to January 2003.
  • Patients were stratified by sex and number of nodes and were randomly assigned to receive either 2 years of treatment with active specific immunotherapy with allogeneic melanoma lysates and low-dose IFN-alpha-2b (arm 1) or high-dose IFN-alpha-2b alone for 1 year (arm 2).
  • IFN-alpha-2b in arm 2 was administered according to the Eastern Cooperative Oncology Group 1684 study regimen.
  • Median OS time exceeds 84 months in arm 1 and is 83 months in arm 2 (P = .56).
  • Five-year OS rate is 61% in arm 1 and 57% in arm 2.
  • Estimated 5-year relapse-free survival (RFS) rate is 50% in arm 1 and 48% in arm 2, with median RFS times of 58 and 50 months, respectively.
  • The incidence of serious adverse events as a result of treatment was the same in both arms, but more severe neuropsychiatric toxicity was seen in arm 2.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Active. Interferon-alpha / therapeutic use. Melanoma / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Expert Rev Vaccines. 2007 Dec;6(6):907-11 [18377354.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 10;25(29):4693; author reply 4693-5 [17925569.001]
  • (PMID = 17513813.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytoskeletal Proteins; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Lipid A; 0 / Melacine; 0 / Recombinant Proteins; 0 / detox adjuvant; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


19. McClay EF, Bogart J, Herndon JE 2nd, Watson D, Evans L, Seagren SL, Green MR, Cancer and Leukemia Group B Study (9235): A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol; 2005 Feb;28(1):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment on the non-TAM containing arm (arm 1) included DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) given every 3 weeks for a total of 5 cycles.
  • Patients treated on arm 2 received the identical chemotherapy regimen as described here with the addition of high-dose TAM (80 mg orally twice per day), which was given for 5 days each cycle starting 1 day before the DDP.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685040.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL, Tyler DS, American College of Surgeons Oncology Group Trial Z0020: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol; 2006 Sep 1;24(25):4196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine in a randomized prospective multi-institutional trial whether the addition of tumor necrosis factor alpha (TNF-alpha) to a melphalan-based hyperthermic isolated limb perfusion (HILP) treatment would improve the complete response rate for locally advanced extremity melanoma.
  • PATIENTS AND METHODS: Patients with locally advanced extremity melanoma were randomly assigned to receive melphalan or melphalan plus TNF-alpha during standard HILP.
  • Grade 4 adverse events were observed in 14 (12%) of 129 patients, with three (4%) of 64 in the melphalan-alone arm and 11 (16%) of 65 in the melphalan-plus-TNF-alpha arm (P = .0436).
  • There were two toxicity-related lower extremity amputations in the melphalan-plus-TNF-alpha arm, and one disease progression-related upper extremity amputation in the melphalan-alone arm.
  • There was no treatment-related mortality in either arm of the study.
  • Sixty-four percent of patients (36 of 58) in the melphalan-alone arm and 69% of patients (40 of 58) in the melphalan-plus-TNF-alpha arm showed a response to treatment at 3 months, with a complete response rate of 25% (14 of 58 patients) in the melphalan-alone arm and 26% (15 of 58 patients) in the melphalan-plus-TNF-alpha arm (P = .435 and P = .890, respectively).
  • CONCLUSION: In locally advanced extremity melanoma treated with HILP, the addition of TNF-alpha to melphalan did not demonstrate a significant enhancement of short-term response rates over melphalan alone by the 3-month follow-up, and TNF-alpha plus melphalan was associated with a higher complication rate.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Extremities. Hyperthermia, Induced. Melanoma / drug therapy. Melphalan / administration & dosage. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 20;25(9):1149; author reply 1149-51 [17369585.001]
  • [CommentIn] J Clin Oncol. 2007 Apr 10;25(11):1449-50; author reply 1450-1 [17416870.001]
  • (PMID = 16943537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA076001
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


21. Lee HW, Ahn SJ, Lee MW, Choi JH, Moon KC, Koh JK: Pseudomelanoma following laser therapy. J Eur Acad Dermatol Venereol; 2006 Mar;20(3):342-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Arm / pathology. Diagnosis, Differential. Female. Humans. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503903.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ: Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother; 2008 Jul-Aug;31(6):591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
  • Twenty-four subjects with metastatic melanoma were treated on a randomized Phase Ib trial evaluating an autologous tumor lysate-pulsed dendritic cell (DC) vaccine with or without interleukin (IL)-2.
  • Therapy was well tolerated with no local vaccine toxicity greater than grade 1 in any arm.
  • Autologous tumor lysate-pulsed DC vaccine with or without IL-2 was well tolerated and immunogenic but failed to induce clinical response in patients with advanced melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1021-32 [11948109.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1440-9 [3262151.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):83-93 [8006603.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):796-807 [9053507.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2268-73 [10051630.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1089-96 [15705911.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):412-9 [16000961.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Clin Exp Immunol. 2005 Dec;142(3):555-68 [16297169.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • (PMID = 18528294.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA059327-12; United States / NCRR NIH HHS / RR / M01 RR000042-441269; United States / NCRR NIH HHS / RR / M01 RR 000042; United States / NCI NIH HHS / CA / P01 CA 59327; United States / NCRR NIH HHS / RR / RR000042-441269; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCI NIH HHS / CA / P01 CA059327-13; United States / NCI NIH HHS / CA / P01 CA059327; United States / NCI NIH HHS / CA / P01 CA059327-12; United States / NCI NIH HHS / CA / CA059327-13
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-2; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS84661; NLM/ PMC2642589
  •  go-up   go-down


23. Er U, Kazanci A, Eyriparmak T, Yigitkanli K, Senveli E: Melanotic schwannoma. J Clin Neurosci; 2007 Jul;14(7):676-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL PRESENTATION: A 54-year-old man presented with hypoesthesia, pain and weakness of the right arm and leg for 4 months.
  • Distinguishing between this tumor and malignant melanoma is important in planning management.
  • [MeSH-major] Melanoma. Neurilemmoma. Spinal Cord Neoplasms

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532504.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


24. Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW: Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol; 2005 May 1;23(13):3079-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The complete response rate was 66.1% in the HT arm and 42.3% in the no-HT arm.
  • Previously irradiated patients had the greatest incremental gain in complete response: 23.5% in the no-HT arm versus 68.2% in the HT arm.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / therapy. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Melanoma / radiotherapy. Melanoma / therapy. Skin Neoplasms / radiotherapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860867.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA42745
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol; 2005 Aug;12(8):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Isolated limb perfusion (ILP) is an effective treatment modality for multiple in-transit melanoma metastases confined to the limb.
  • Out of 100 tumor necrosis factor (TNF)-based ILPs with TNF and melphalan (TM-ILPs) in melanoma patients between March 1991 and July 2003, 25 repeat ILP procedures were performed in 21 patients in whom prior ILP treatment failed.
  • All patients had bulky and/or numerous lesions and were treated with mild hyperthermic TM-ILP by using 2 to 4 mg of TNF and 10 to 13 mg/L of limb volume for the leg and arm, respectively.
  • The subgroup of patients qualifying for repeat ILP represents a relatively favorable biological behavior of the melanoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / administration & dosage. Neoplasm Seeding. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Disease Progression. Drug Therapy, Combination. Female. Humans. Leg. Male. Middle Aged. Retreatment. Treatment Failure

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968498.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


26. Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM: Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol; 2010 May 10;28(14):2460-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Conflicting data have been reported concerning the prognostic value of autoimmune antibodies in patients with melanoma treated with adjuvant interferon alfa-2b (IFN).
  • Occurrence of autoantibodies during follow-up was higher in the PEG-IFN-treated patients (18% in the observation arm v 52% in the PEG-IFN arm).
  • CONCLUSION: Appearance of autoimmune antibodies is neither a prognostic nor a predictive factor for improved outcome in patients with melanoma treated with PEG-IFN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Autoantibodies / blood. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Polyethylene Glycols / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antinuclear; 0 / Antineoplastic Agents; 0 / Autoantibodies; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / anti-thyroglobulin; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


27. Velasco-Velázquez MA, Salinas-Jazmín N, Mendoza-Patiño N, Mandoki JJ: Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells. Cancer Cell Int; 2008;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells.
  • 4-HC affects the cytoskeletal stability and decreases cell adhesion and motility of the melanoma cell line B16-F10.
  • The present study determined the participation of paxillin in the reported effects of 4-HC and analyzed the role of paxillin in the formation of melanoma metastases.
  • We also studied the importance of paxillin in metastasis by transfecting melanoma cells with paxillin-siRNA.
  • Transfection produced a modest reduction on metastatic potential, indicating that: i) paxillin plays a role as inducer of melanoma metastasis; and ii) paxillin downregulation is not sufficient to explain the antimetastatic effect of 4-HC.
  • Treatment with 4-HC produced a downregulation of Adhesion Regulating Molecule-1 (ARM-1), which correlated with a decreased adhesion of melanoma cells to lung slides.
  • In contrast, the role of ARM-1 reduced expression in the effects of 4-HC is still to be clarified.
  • The antimetastatic effect of 4-HC suggests that this compound, or others with similar mode of action, might be useful for the development of adjuvant therapies for melanoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1994 Jan;89(1):432-49 [8281678.001]
  • [Cites] Physiol Rev. 2004 Oct;84(4):1315-39 [15383653.001]
  • [Cites] Connect Tissue Res. 1996;34(3):161-74 [9023046.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7437-44 [9054445.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):6906-14 [9372922.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22435-41 [9712867.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3331-6 [9808620.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):67-77 [9926921.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2843-6 [10383144.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2507-18 [10436008.001]
  • [Cites] Rev Invest Clin. 1999 May-Jun;51(3):183-93 [10466009.001]
  • [Cites] J Cell Biol. 2000 Mar 6;148(5):957-70 [10704446.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):27155-64 [10823820.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):641-8 [10919708.001]
  • [Cites] Mol Biol Cell. 2000 Sep;11(9):3247-63 [10982414.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Protein Sci. 2005 Mar;14(3):644-52 [15689512.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1445-51 [15770719.001]
  • [Cites] FEBS J. 2005 Apr;272(8):1833-44 [15819879.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4754-64 [15870699.001]
  • [Cites] Clin Exp Immunol. 2005 Jun;140(3):443-9 [15932505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11041-6 [16040804.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1832-41 [16212439.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9851-60 [16267008.001]
  • [Cites] J Cell Sci. 2005 Dec 15;118(Pt 24):5835-47 [16317044.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):9-15 [16360410.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):629-43 [16375667.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3689-98 [16462764.001]
  • [Cites] J Cell Biochem. 2006 Aug 15;98(6):1507-16 [16552730.001]
  • [Cites] J Mol Biol. 2006 Jul 28;360(5):1043-52 [16815440.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 6;348(4):1463-71 [16920067.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):163-80 [17084981.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):38040-7 [10986280.001]
  • [Cites] Nat Cell Biol. 2000 Dec;2(12):E231-6 [11146675.001]
  • [Cites] Nat Protoc. 2006;1(5):2315-9 [17406473.001]
  • [Cites] Ecotoxicol Environ Saf. 1986 Feb;11(1):91-9 [3956434.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2635-45 [7537852.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):104-8 [7615962.001]
  • [Cites] Lab Invest. 1993 Feb;68(2):192-203 [7680081.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3831-6 [8033103.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):917-23 [11396185.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):793-805 [11715046.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):330-5 [11774284.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):901-15 [11784865.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34391-400 [12110680.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):673-83 [12446743.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1593(2-3):115-20 [12581855.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Scand J Immunol. 2003 May;57(5):439-45 [12753500.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):683-9 [12866027.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):359-74 [12884911.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):690-2 [12894172.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):179-86 [12957356.001]
  • [Cites] Science. 1992 Aug 14;257(5072):967-71 [1354393.001]
  • [Cites] J Cell Biol. 1992 Nov;119(4):893-903 [1385444.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] BMC Cancer. 2004 May 7;4:18 [15132756.001]
  • [Cites] Fundam Clin Pharmacol. 1996;10(6):504-10 [8985719.001]
  • (PMID = 18492274.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2429896
  •  go-up   go-down


28. al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G, Chouaib S: Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol; 2009 Jan;130(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our laboratory has previously demonstrated that an attenuated strain of S. typhimurium engineered to express IL2 (designated strain GIDIL2) has demonstrable immunopotentiating properties, particularly affecting the innate arm of the immune system.
  • In the present study, we wished to explore the properties of IL2-expressing Salmonella as an oncolytic agent in the highly tumorigenic B16F1 melanoma mouse model and shed light on its mechanism of action.
  • A treatment regimen involving multiple low doses of GIDIL2 was more efficacious than a single high dose regimen, resulting in extension of animal survival well beyond the normal 30 day post implantation period typically observed in this aggressive melanoma tumor model.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849195.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


29. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, Cassidanius A, Lemarre P, Volteau C, Labarrière N, Jotereau F, Dréno B: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother; 2007 Nov;56(11):1853-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
  • The first analysis of our clinical trial on interest of using tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma was published in 2002 [5].
  • In the group with only one invaded lymph node, the estimated relapse rate was significantly lower (P (adjusted) = 0.0219) and the overall survival was increased (P (adjusted) = 0.0125) in the TIL+IL-2 arm compared with the IL-2 only arm.
  • This study, with a very long follow up (median of almost 10 years), postulates for the first time relationship between TIL efficiency in stage III melanoma (AJCC) and number of invaded lymph nodes, indicating that tumor burden might be a crucial factor in the production of an effective in vitro expansion of T cells specific for autologous tumor antigen, a finding which could be of value in future vaccine development for the treatment of melanoma.
  • [MeSH-major] Adjuvants, Immunologic. Adoptive Transfer. Lymphocytes, Tumor-Infiltrating / immunology. Melanoma / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549472.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic
  •  go-up   go-down


30. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK, C-100-21 Study Group: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol; 2008 Feb 20;26(6):955-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
  • PURPOSE: To assess the antitumor activity of vitespen (autologous, tumor- derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice.
  • Patients randomly assigned to the vitespen arm received variable number of injections (range, 0 to 87; median, 6) in part because of the autologous nature of vitespen therapy.
  • Intention-to-treat analysis showed that overall survival in the vitespen arm is statistically indistinguishable from that in the PC arm.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Heat-Shock Proteins / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - heat shock protein 90 beta family member 1 - data and references .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 Aug 1;26(22): 3819
  • (PMID = 18281670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84479
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Heat-Shock Proteins; 0 / Interleukin-2; 492448-75-6 / vitespin; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


31. Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C, German Dermatologic Cooperative Oncology Group: Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res; 2008 Oct;18(5):353-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
  • To evaluate the efficacy and safety of vindesine in patients with metastatic melanoma after complete metastasectomy.
  • Three-year overall survival rate was 54.9% (37 patients) for patients receiving vindesine in comparison to 43.6% (31 patients) in the observation arm (P=0.07).
  • Adjuvant treatment with vindesine did not significantly prolong disease free or overall survival in high-risk melanoma patients.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Vindesine / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Melanoma Res. 2009 Apr;19(2):123-4 [19289925.001]
  • (PMID = 18781134.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; RSA8KO39WH / Vindesine
  • [Investigator] Hermes B; Kohl P; Mohr P; Breitbart EW; Koch HJ; Schreiter K; Stein A; Sebastian G; Meurer M; Kellner I; Linse R; Wagner S; Goos M; Neuber K; Moll I; Gutzmer R; Kapp A; Jess P; Näher H; Petzoldt D; Djawari D; Petzold O; Pföhler C; Reinhold U; Tilgen W; Kaatz M; Elsner P; Möller M; Hauschild A; Jöckel A; Mauch C; Krieg T; Hoffmann U; Schadendorf D; Pierfrancesco Z; Daniel E; Vigl E; Böttjer J; Hartig C; Stadler R; Nashan D; Luger T; Pelzer P; Hölzle E; Coras B; Stolz W; Landthaler M; Ebisch MA; Zimmermann R; Gross G; Radny P; Eigentler TK; Garbe C; Mooser G; Lange M; Peter RU; Heinzerling L; Dummer R; Knopf B
  •  go-up   go-down


32. Neuss H, Reetz C, Raue W, Koplin G, Mall JW: Postoperative surgical complications after radical axillary lymph node dissection in melanoma disease result in increased pain. Int Surg; 2010 Apr-Jun;95(2):166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative surgical complications after radical axillary lymph node dissection in melanoma disease result in increased pain.
  • We registered a VAS score of 10 in patients at rest during the first 3 postoperative days, but after mobilization of the arm, patients had significantly more pain (P < 0.0001).

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718325.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Kane JM 3rd, Kraybill WG: Radical operations for soft tissue sarcomas. Surg Oncol Clin N Am; 2005 Jul;14(3):633-48, viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Amputation / history. Arm. Artificial Limbs. Combined Modality Therapy. Hemipelvectomy / history. History, 19th Century. History, 20th Century. Humans. Leg. Limb Salvage. Reconstructive Surgical Procedures. Replantation. Spinal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978433.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


34. Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res; 2006 Apr 15;12(8):2526-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
  • PURPOSE: Two clinical trials were conducted to evaluate the clinical efficacy and immunologic impact of vaccination against the tyrosinase protein plus systemic interleukin 2 (IL-2) administration in patients with advanced metastatic melanoma.
  • EXPERIMENTAL DESIGN: Full-length tyrosinase was employed as an immunogen to induce diverse immunologic responses against a commonly expressed melanoma antigen.
  • Heterologous prime/boost vaccination with recombinant vaccinia and fowlpox vectors encoding tyrosinase was first explored in a randomized three-arm phase II trial, in which vaccines were administered alone or concurrently with low-dose or high-dose IL-2.
  • CONCLUSIONS: Whereas prime/boost immunization with recombinant vaccinia and fowlpox viruses enhanced antityrosinase immunity in some patients with metastatic melanoma, it was ineffective alone in mediating clinical benefit, and in combination with IL-2 did not mediate clinical benefit significantly different from that expected from treatment with IL-2 alone.
  • [MeSH-major] Cancer Vaccines / immunology. DNA, Recombinant / immunology. Immunization, Secondary / methods. Interleukin-2 / therapeutic use. Melanoma / therapy. Vaccination / methods

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3124-6 [8205528.001]
  • [Cites] Eur J Immunol. 1994 Mar;24(3):759-64 [8125142.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4685-92 [7722321.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1343-8 [7543520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8125-9 [7667256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Eur J Immunol. 1996 Jan;26(1):224-30 [8566071.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):1965-71 [8642306.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 [8876137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53 [8876138.001]
  • [Cites] Curr Opin Immunol. 1996 Oct;8(5):628-36 [8902387.001]
  • [Cites] Vaccine. 1997 Apr-May;15(6-7):759-68 [9178479.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601 [9362157.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):296-301 [9443408.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2099-106 [9498746.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6985-92 [9862734.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4446-8 [15483013.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1218-27 [15718319.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):755-9 [10597191.001]
  • [Cites] Vaccine. 2000 Apr 3;18(19):2015-22 [10706963.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44 [10944556.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):252-7 [10966567.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3964-73 [11099326.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] J Immunother. 2001 May-Jun;24(3):212-20 [11394498.001]
  • [Cites] Eur J Immunol. 2001 Sep;31(9):2690-701 [11536167.001]
  • [Cites] Clin J Oncol Nurs. 2001 Sep-Oct;5(5):207-17 [11905416.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Immunol Methods. 2002 Aug 1;266(1-2):87-103 [12133625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):188-94 [12569574.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2973-80 [12912944.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1595-9 [14996715.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2122-32 [15169798.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3989-96 [15459222.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5 [2679456.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4651-7 [7722317.001]
  • (PMID = 16638862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z01 SC003811-32; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / DNA, Recombinant; 0 / Immunoglobulin G; 0 / Interleukin-2; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma; EC 1.14.18.1 / Monophenol Monooxygenase
  • [Other-IDs] NLM/ NIHMS35505; NLM/ PMC2151202
  •  go-up   go-down


35. McArthur GJ, Banwell ME, Cook MG, Powell BW: The role of sentinel node biopsy in the management of melanocytic lesions of uncertain malignant potential (MUMP). J Plast Reconstr Aesthet Surg; 2007;60(8):952-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sentinel node biopsy is recognised to provide unmatched prognostic information in melanoma patients, but has recently been advocated for diagnostic purposes in MUMP.
  • We present the case of a seven-year-old girl who presented with a six-month history of a changing pigmented lesion on her left upper arm.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616368.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst; 2010 Apr 7;102(7):493-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
  • BACKGROUND: Based on previous meta-analyses of randomized controlled trials (RCTs), the use of interferon alpha (IFN-alpha) in the adjuvant setting improves disease-free survival (DFS) in patients with high-risk cutaneous melanoma.
  • METHODS: We conducted a systematic review and meta-analysis to examine the effect of IFN-alpha on DFS and OS in patients with high-risk cutaneous melanoma.
  • RESULTS: The meta-analysis included 14 RCTs, published between 1990 and 2008, and involved 8122 patients, of which 4362 patients were allocated to the IFN-alpha arm.
  • CONCLUSION: In patients with high-risk cutaneous melanoma, IFN-alpha adjuvant treatment showed statistically significant improvement in both DFS and OS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy


37. Zand S, Lio PA, Mackool BT, Duncan LM: A slightly erythematous, firm papule on the upper arm--quiz case. Arch Dermatol; 2005 Jan;141(1):93-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A slightly erythematous, firm papule on the upper arm--quiz case.
  • [MeSH-major] Arm. Melanoma, Amelanotic / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655153.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS: Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol; 2008 Apr;31(2):173-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
  • OBJECTIVE: To evaluate the safety and activity of large multivalent immunogen (LMI), prepared by immobilizing autologous tumor cell plasma membrane on 5-microm diameter silica beads, in patients with melanoma and renal cell carcinoma (RCC).
  • METHODS: Thirty patients with stage IV metastatic melanoma and 31 patients with stage IV RCC were randomly assigned to 1 of 3 trial arms and received monthly treatment with (1) LMI alone, (2) cyclophosphamide followed 8 days later with LMI, or (3) the same treatment as in arm 2 with IL-2 given for 5 days beginning 1 week after LMI administration.
  • For patients with melanoma, median overall survival time for all 30 patients was 20.4 months [95% confidence interval (CI): 8.0-not assessable], and median progression-free survival was 2.8 months (95% CI: 1.9-6.3).
  • [MeSH-major] Antigens, Neoplasm / therapeutic use. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Melanoma / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391603.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Interleukin-2; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


39. Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M: Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol; 2010 Mar;146(3):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes.
  • OBJECTIVE: To evaluate the diagnostic sensitivity of fluorescence in situ hybridization (FISH) using probes targeting 6p25, 6q23, 11q13, and Cep6 in melanoma subtypes.
  • DESIGN: Blinded comparison of chromosomal copy number changes detected using FISH targeting 6p25, 6q23, 11q13, and Cep6 in benign nevi and melanoma subtypes.
  • PARTICIPANTS: One hundred ten individuals with benign nevi and 123 with melanoma (70 superficial spreading, 28 lentigo maligna, 22 nodular, and 3 acral lentiginous melanomas).
  • MAIN OUTCOME MEASURES: Sensitivity of previously developed criteria using FISH using probes targeting 6p25, 6q23, 11q13, and Cep6 in the melanoma subtypes.
  • CONCLUSIONS: Heterogeneous changes in melanoma occur at the molecular level, and the changes are different among melanoma subtypes.
  • Clonal abnormalities in chromosome 6 with increased copies of the short arm relative to the long arm are common in all melanoma subtypes, suggesting that isochromosome 6 is common in all variants of cutaneous melanoma subtypes.
  • [MeSH-major] Cyclin D1 / genetics. DNA, Neoplasm / analysis. DNA-Binding Proteins / genetics. In Situ Hybridization, Fluorescence / methods. Melanoma / diagnosis. Proto-Oncogene Proteins c-myb / genetics. Skin Neoplasms / diagnosis. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231497.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-myb; 0 / RREB1 protein, human; 0 / Transcription Factors; 136601-57-5 / Cyclin D1
  •  go-up   go-down


40. Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A: Utility of adjuvant systemic therapy in melanoma. Ann Oncol; 2009 Aug;20 Suppl 6:vi30-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of adjuvant systemic therapy in melanoma.
  • The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease.
  • Observation is still an appropriate control arm in adjuvant clinical trials.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2444-58 [10856105.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):841-6 [20048184.001]
  • [Cites] Lancet. 2001 Sep 15;358(9285):866-9 [11567700.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2147-53 [11677100.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2058-66 [11956266.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2067-75 [11956267.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4181-90 [12377961.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4549-54 [12454111.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2883-8 [12885805.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):241-52 [12927565.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):53-61 [14665609.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1670-7 [15014018.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1036-44 [8164027.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] Lancet. 1998 Jun 27;351(9120):1905-10 [9654256.001]
  • [Cites] Lancet. 2005 Oct 1;366(9492):1189-96 [16198768.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8655-63 [16260701.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2078-85 [17513813.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):509-15 [18083374.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1195-201 [18281266.001]
  • [Cites] Lancet. 2008 Jul 12;372(9633):117-26 [18620949.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):939-44 [19139440.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1146-9 [11379605.001]
  • (PMID = 19617295.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC2712588
  •  go-up   go-down


41. Santos GC, Zielenska M, Prasad M, Squire JA: Chromosome 6p amplification and cancer progression. J Clin Pathol; 2007 Jan;60(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent findings suggest that a central part of the short arm of chromosome 6p harbours one or more oncogenes directly involved in tumour progression.
  • Melanoma cytogenetics has consistently identified aberrations of chromosome 6, and a correlation with lower overall survival has been described.

  • Genetics Home Reference. consumer health - chromosome 6.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 May 20;89(3):305-10 [10861509.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):431-40 [10930378.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4526-30 [10969802.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):1025-9 [11029508.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 1;122(1):13-7 [11104026.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):355-62 [11196186.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Feb;42(2):313-7 [11157859.001]
  • [Cites] Br J Cancer. 2001 Feb;84(4):499-503 [11207045.001]
  • [Cites] Hum Genet. 2001 Feb;108(2):98-104 [11281459.001]
  • [Cites] Urology. 2001 May;57(5):986-92 [11337313.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1239-44 [11351257.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):80-4 [11391625.001]
  • [Cites] Hum Genet. 1984;66(1):46-53 [6583158.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):663-71 [3524791.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jan;37(1):95-102 [2917337.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3817-23 [8033101.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4764-8 [8062277.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Sep;76(2):112-5 [7923058.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Mar;80(1):40-6 [7697631.001]
  • [Cites] Oncogene. 2005 May 26;24(23):3737-47 [15735714.001]
  • [Cites] Cytometry. 2001 Aug 15;46(4):222-32 [11514955.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):57-63 [11520568.001]
  • [Cites] J Invest Dermatol. 2001 Sep;117(3):683-6 [11564177.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1900-13 [11747333.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Sep;14(1):15-21 [8527379.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5269-78 [8652842.001]
  • [Cites] J Cutan Pathol. 1996 Oct;23(5):391-7 [8915847.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jan;18(1):59-65 [8993981.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):81-9 [9006325.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2223-9 [9649137.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3555-60 [9721860.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):167-74 [9739020.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1615-21 [9811354.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):306-14 [10092128.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):114-21 [10096241.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1731s-1735s [10197588.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):87-93 [10214355.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):104-7 [10337993.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):205-11 [10379866.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):435-42; discussion 432-3 [10416984.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):652-8 [10492642.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Oct 1;114(1):35-41 [10526533.001]
  • [Cites] Melanoma Res. 2004 Dec;14(6):473-8 [15577317.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Feb;157(1):1-11 [15676140.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):392-403 [15660435.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):935-41 [15756261.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):294-301 [15834944.001]
  • [Cites] Mol Cancer. 2005;4(1):16 [15876350.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):967-71 [11861365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8886-91 [12077300.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):632-41 [12152163.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):355-65 [12402305.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):121-8 [12508240.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):151-8 [12508243.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):189-97 [12508247.001]
  • [Cites] Genome Biol. 2002;3(12):RESEARCH0075 [12537564.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Mar;141(2):128-37 [12606130.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3109-17 [12406872.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2872-80 [12782593.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 1;144(1):12-7 [12810250.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 1;146(1):8-15 [14499690.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):215-25 [14506695.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1765-70 [14578177.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):11-21 [14603437.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):57-65 [14618616.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):285-93 [14695341.001]
  • [Cites] Hum Mol Genet. 2004 Jan 15;13(2):191-202 [14645202.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1627-30 [14716298.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2250-63 [14968109.001]
  • [Cites] Mod Pathol. 2004 May;17(5):561-7 [15001998.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):143-9 [15140403.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5616-23 [15122326.001]
  • [Cites] BMC Cancer. 2004 Aug 7;4:45 [15298715.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):546-51 [15487452.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):603-13 [16036111.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Aug;161(1):20-7 [16080954.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6441-9 [16007192.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):72-82 [16180235.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1191-6 [16251874.001]
  • [Cites] J Pathol. 1999 Oct;189(2):230-5 [10547580.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5687-91 [10582685.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):113-6 [10585593.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):392-402 [10719370.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 15;118(2):136-43 [10748294.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1968-73 [10766187.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):370-9 [10862045.001]
  • (PMID = 16790693.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 89
  • [Other-IDs] NLM/ PMC1860600
  •  go-up   go-down


42. Liao YP, Schaue D, McBride WH: Modification of the tumor microenvironment to enhance immunity. Front Biosci; 2007;12:3576-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The same lack of knowledge impacts outcomes of clinical immunotherapy (IT) trials that have so far not broken through the ceiling of 10% success rate that seems to exist even in melanoma.
  • It seems obvious that more could be achieved by combining therapies that tackle malignancies from multiple angles, with the tumor microenvironment conditioned to support a powerful effector arm generated by IT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485323.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-101752
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 346
  •  go-up   go-down


43. Selvaggi K, Abrahm J: Metastatic spinal cord compression: the hidden danger. Nat Clin Pract Oncol; 2006 Aug;3(8):458-61; quiz following 461
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 47-year-old male underwent resection of a left-shoulder melanoma in 1997.
  • In April 2005, the patient commenced temozolomide and underwent radiation therapy to the left arm for pain thought to be caused by an increase in size of his melanoma metastasis.
  • In August 2005 the patient reported persistent and worsening arm pain, despite a further course of radiotherapy in June 2005.
  • DIAGNOSIS: Metastatic melanoma to the cervical spine (C7 vertebra) with spinal cord compression.
  • [MeSH-major] Melanoma / secondary. Melanoma / therapy. Pain / etiology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894391.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Uren RF, Howman-Giles RB, Chung D, Thompson JF: Role of lymphoscintigraphy for selective sentinel lymphadenectomy. Cancer Treat Res; 2005;127:15-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is especially important in melanoma patients, since high-quality LS can identify the actual lymphatic collecting vessels as they drain into each SN.
  • Drainage to the epitrochlear region from the hand and arm is more common than was previously thought as is drainage to the popliteal region from the foot and leg.
  • Interval nodes, which lie along the course of a lymphatic vessel between a melanoma site and a recognised node field, are not uncommon especially on the trunk.
  • [MeSH-minor] Breast Neoplasms / pathology. Female. Humans. Lymphatic Metastasis. Male. Melanoma / secondary. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209076.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


45. Aguilar García G, Serrano Falcón C, Serrano Falcón Mdel M, Carmona MD, Linares Solano J, Serrano Ortega S: [Cutaneous necrosis due to interferon alpha in a patient with melanoma]. Actas Dermosifiliogr; 2006 Oct;97(8):539-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
  • [Transliterated title] Necrosis cutánea por interferón alfa en paciente con melanoma.
  • We present the case of a 55-year-old male with melanoma in the right retroauricular region who had cutaneous necrosis only in one of the injection sites after adjuvant treatment with interferon (IFN alpha 2b) according to the Kirkwood proposed regime.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Interferon-alpha / adverse effects. Melanoma / drug therapy. Necrosis / chemically induced. Skin / pathology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Arm. Chemotherapy, Adjuvant. Debridement. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Ointments. Recombinant Proteins. Skin Ulcer / chemically induced. Skin Ulcer / drug therapy. Skin Ulcer / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067536.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ointments; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


46. Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, Galeassi N, Neese PY, Grosh WW, Nail CJ, Ross M, von Mehren M, Haas N, Boisvert ME, Kirkwood JM: Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother; 2010 Jul-Aug;33(6):630-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
  • Analyses included 194 patients who received either IFA-AN or IFA-VG for all vaccines, and a subset of 93 patients best matched by study arm for vaccine antigens (12 melanoma peptides restricted by major histocompatibility complex class I, 12MP; plus a tetanus helper peptide, tet) administered with IFA but without granulocyte macrophage-colony stimulating factor.
  • CD8 T-cell response rates to the 12 melanoma peptides were 53% [95% confidence interval (CI), 44%, 61%)] for IFA-AN and 46% [95% CI, 32%, 59%)] for IFA-VG.
  • Despite the necessarily retrospective nature of the analysis and limitations of multiple comparisons, our summary data support the use of IFA-VG as an adjuvant with multipeptide vaccines in melanoma patients.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TALLOW .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3012-24 [11595689.001]
  • [Cites] J Clin Oncol. 2011 Jul 20;29(21):2924-32 [21690475.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2539-48 [8805655.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2099-106 [9498746.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):359-71 [15378283.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3080-6 [15728523.001]
  • [Cites] J Immunother. 2006 Mar-Apr;29(2):224-31 [16531823.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6386-95 [17975151.001]
  • [Cites] J Immunother. 2008 May;31(4):420-30 [18391753.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4973-80 [18809608.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3538-49 [18923873.001]
  • [Cites] Vaccine. 2009 Mar 10;27(11):1764-70 [19185050.001]
  • [Cites] Clin Cancer Res. 2009 Nov 15;15(22):7036-44 [19903780.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • (PMID = 20551833.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA118386-05; United States / NCI NIH HHS / CA / NIH R01 CA118386; United States / NCI NIH HHS / CA / R21 CA103528-01; United States / NCI NIH HHS / CA / P30 CA044579; United States / NCRR NIH HHS / RR / NIH M01 RR00847; United States / NCI NIH HHS / CA / R01 CA118386-02; United States / NCI NIH HHS / CA / R21 CA103528-02; United States / NCI NIH HHS / CA / P30 CA044579-18; United States / NCI NIH HHS / CA / R01 CA118386-03; United States / NCI NIH HHS / CA / NIH R21 CA103528; United States / NCI NIH HHS / CA / R01 CA118386; United States / NCI NIH HHS / CA / R21 CA103528; United States / NCI NIH HHS / CA / R01 CA118386-04; United States / NCI NIH HHS / CA / NIH/NCI P30 CA44579; United States / NCRR NIH HHS / RR / M01 RR000847
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Fats; 0 / Peptide Fragments; 0 / Vaccines, Subunit; 61789-97-7 / tallow; 9007-81-2 / Freund's Adjuvant
  • [Other-IDs] NLM/ NIHMS221635; NLM/ PMC3218563
  •  go-up   go-down


47. Mensing C, Livingstone E, Schwarz T, Hauschild A: Eczematous malignant melanoma: a wolf in sheep's clothing. Onkologie; 2009 Apr;32(4):206-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eczematous malignant melanoma: a wolf in sheep's clothing.
  • BACKGROUND: The clinical diagnosis of amelanotic melanoma is still a challenge.
  • CASE REPORT: A 72-year-old patient was first referred to us for the excision of a melanoma of the chin.
  • In the first examination, we discovered another melanoma of the trunk.
  • Apart from these melanomas, physical examination revealed an 8 cm x 5 cm large erythematous plaque on the left upper arm.
  • Surprisingly, the pathology report showed typical features of a malignant melanoma.
  • CONCLUSIONS: Amelanotic melanoma may appear as an erythematous macula or plaque; clinical symptoms are erythema, edema, pruritus or a slow increase in size and hypopigmentation or discoloration.
  • [MeSH-major] Eczema / diagnosis. Eczema / etiology. Melanoma / complications. Melanoma / diagnosis. Skin Neoplasms / complications. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19372718.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


48. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C: Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother; 2009 Jun;32(5):498-507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
  • We injected intradermally protamine-stabilized mRNAs coding for Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin in 21 metastatic melanoma patients.
  • During treatment the frequency of Foxp3+/CD4+ regulatory T cells was significantly decreased upon mRNA vaccination in peripheral blood of the patients in the KLH arm, whereas myeloid suppressor cells (CD11b+HLA-DR lo monocytes) were reduced in the patients not receiving KLH.
  • [MeSH-major] Antigens, Neoplasm / genetics. Antigens, Neoplasm / immunology. Bone Neoplasms / immunology. Bone Neoplasms / therapy. Cancer Vaccines. Immunotherapy, Active. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Melanoma / immunology. Melanoma / therapy. Myeloid Cells / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD11b. Antigens, CD4. Cell Proliferation. Feasibility Studies. Female. Forkhead Transcription Factors. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. HLA-DR Antigens. Hemocyanin / metabolism. Humans. Injections, Intradermal. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Staging. Protamines / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Messenger / therapeutic use. Remission Induction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609242.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00204607
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD4; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / HLA-DR Antigens; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / PRM1 protein, human; 0 / Protamines; 0 / RNA, Messenger; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


49. Brown DA, Canning MT, Nay SL, Pena AV, Yarosh DB: Bicyclic monoterpene diols stimulate release of nitric oxide from skin cells, increase microcirculation, and elevate skin temperature. Nitric Oxide; 2006 Aug;15(1):70-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bicyclic monoterpene diols (BMTd) stimulate nitric oxide synthesis in melanoma and neuronal cells, representing cell types arising from embryonic neural crest tissue.
  • We found that twice daily application of 1mM BMTd lotion significantly increased arm skin temperature by 0.5 degrees C in 14 days compared to placebo, while a 2 mM mixture significantly increased skin temperature by 0.3 degrees C in 7 days (P < or = 0.05; ANOVA).

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626981.001).
  • [ISSN] 1089-8603
  • [Journal-full-title] Nitric oxide : biology and chemistry
  • [ISO-abbreviation] Nitric Oxide
  • [Language] ENG
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2,3-pinanediol; 0 / 2-exo,3-endo-camphanediol; 0 / Boranes; 0 / Bornanes; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


50. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • In patients with extremity STS or bulky melanoma in-transit metastases, the local tumor burden may be so problematic that, even in patients with systemically metastasized disease, an amputation may be inevitable.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • METHODS: From 1991 to 2003, of 339 tumor necrosis factor alpha (TNF)-based ILPs, 51 procedures were performed for either Stage IV STS (n = 37 patients) or Stage IV melanoma (n = 14 patients).
  • In the patients with Stage IV melanoma, the complete response rate was 43%.
  • All patients with melanoma preserved their limb during a median survival of 7 months.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


51. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P: Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res; 2005 Aug;15(4):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
  • This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma.
  • The response rates were 8% (2/25) in arm A, 13% (4/31) in arm B, 12% (3/25) in arm C and 24% (6/25) in arm D.
  • There were no significant differences in survival (arm A, 11.1 months; arm B, 9.8 months; arm C, 9.1 months; arm D, 7.5 months; P=0.62).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon Type I / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034308.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Interferon-alpha; 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; BOLD protocol
  •  go-up   go-down


52. Price KL, Herlyn M, Dent CL, Gewert DR, Linge C: The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res; 2005 Apr;15(2):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of interferon-alpha transcription defects in malignant melanoma.
  • The type I interferons, interferon-alpha (IFN-alpha) and interferon-beta (IFN-beta), are situated on the short arm of chromosome 9, specifically 9p21-22.
  • The identification of 9p rearrangements in both melanoma precursor lesions (dysplastic naevi) and primary lesions has implicated the 9p locus in the early stages of melanoma development.
  • Recent evidence has demonstrated that metastatic melanoma cell lines have a specific loss of IFN-alpha gene expression, a defect that appears to occur at the level of transcription.
  • In this study, we examined the expression of IFN-alpha in cell lines isolated from the various stages of melanoma progression, with a view to determine the prevalence of the IFN-alpha transcription defects exhibited by malignant melanoma, and to assess whether the loss of IFN-alpha expression was particular to a certain stage of melanoma progression.
  • We showed that all the melanoma cell lines tested (n=20) demonstrated an inability to express IFN-alpha, a defect that was reflected in the apparent inactivity of the IFN-alpha promoter.
  • These defects were found to occur in cells isolated from early melanomas, lending support to the hypothesis that IFN-alpha has a role in the aetiology of malignant melanoma.
  • [MeSH-major] Antineoplastic Agents. Gene Expression Regulation, Neoplastic. Interferon-alpha / genetics. Melanoma / genetics. Skin Neoplasms / genetics. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846141.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Interferon-alpha; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


53. Russo A, Coupland SE, O'Keefe M, Damato BE: Choroidal melanoma in a 7-year-old child treated by trans-scleral local resection. Graefes Arch Clin Exp Ophthalmol; 2010 May;248(5):747-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal melanoma in a 7-year-old child treated by trans-scleral local resection.
  • PURPOSE: To report a choroidal melanoma in a 7-year-old child treated by trans-scleral local resection and adjuvant brachytherapy with a family history of neurofibromatosis type I (NF1) and cutaneous melanoma.
  • PATIENT AND METHODS: A 7-year-old child was referred for treatment of a choroidal tumor in her left eye with a differential diagnosis of melanoma, neurilemmoma, leiomyoma, and neurofibroma.
  • RESULTS: Histopathology and immunohistochemistry of the specimen diagnosed an amelanotic melanoma of spindle cell type, with a moderately high number of mitoses (7/40 HPF).
  • Multiplex ligation-dependent probe amplification (MLPA) analysis showed two copies of chromosome 3, three copies of the short arm of chromosome 6, and two copies of chromosome 8, strongly suggesting a good prognosis.
  • [MeSH-major] Choroid Neoplasms / surgery. Melanoma / surgery. Ophthalmologic Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol (Copenh). 1970;48(6):1113-28 [5537253.001]
  • [Cites] Ann Surg. 1972 Jan;175(1):86-104 [4621893.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Apr;245(4):522-33 [17111148.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):918-23 [10900104.001]
  • [Cites] Ophthalmology. 1991 Nov;98(11):1662-6 [1800926.001]
  • [Cites] Am J Ophthalmol. 1998 Jun;125(6):745-66 [9645714.001]
  • [Cites] Arch Ophthalmol. 1981 Dec;99(12):2133-6 [7305710.001]
  • [Cites] Arch Ophthalmol. 2009 Apr;127(4):423-9 [19365018.001]
  • (PMID = 20143236.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ruthenium Radioisotopes
  •  go-up   go-down


54. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT: Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res; 2009 Dec 15;15(24):7711-7718
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
  • PURPOSE: The combination of the oral alkylating agent temozolomide and the oral multikinase inhibitor sorafenib was evaluated in advanced melanoma patients.
  • EXPERIMENTAL DESIGN: Patients with metastatic melanoma (n = 167) were treated on four arms.
  • Patients without brain metastases or prior temozolomide were randomized between arm A: extended dosing of temozolomide (75 mg/m(2) temozolomide daily for 6 of every 8 weeks) and arm B: standard dosing (150 mg/m(2) temozolomide daily for 5 of every 28 days).
  • Patients previously treated with temozolomide were enrolled on arm C: extended dosing of temozolomide.
  • Patients with brain metastases and no prior temozolomide were assigned to arm D: standard dosing.
  • The median PFS for patients on arm A, B, C, and D was 5.9, 4.2, 2.2, and 3.5 months, respectively.
  • No significant differences in toxicity were observed between arms A and B except for more grade 3 to 4 lymphopenia in arm A.
  • CONCLUSION: Temozolomide plus sorafenib was well tolerated and showed activity in melanoma patients without prior history of temozolomide.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996224.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA104884; United States / NCI NIH HHS / CA / R01 CA118871; United States / NCI NIH HHS / CA / P50 CA093372; United States / NCI NIH HHS / CA / K23 CA120862; United States / NCI NIH HHS / CA / CA093372-05
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


55. Fujiwara M, Suzuki A, Mizukami T, Nagata T, Ito T, Fukamizu H: Mid-arm lymph nodes dissection for melanoma. J Plast Reconstr Aesthet Surg; 2010 Sep;63(9):1561-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mid-arm lymph nodes dissection for melanoma.
  • An interval node in the upper limb termed the mid-arm node was recently identified.
  • We report a patient with metastatic melanoma of the mid-arm node and the epitrochlear node at 10 years after removal of the primary tumour from the forearm and therapeutic axillary lymph node dissection.
  • The mid-arm node is located halfway up the upper arm on the medial intermuscular septum, at the site where the brachial vessels, the median nerve and the ulnar nerve run adjacent to each other.
  • The mid-arm node lies adjacent to the basilic vein where lymphatic vessels ascend and converge.
  • This is the first report regarding the surgical anatomy of the mid-arm node.
  • [MeSH-major] Forearm / surgery. Lymphatic Vessels / surgery. Melanoma / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20227935.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R, Dermatologic Cooperative Oncology Group: Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol; 2005 Dec 10;23(35):9001-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
  • PURPOSE: Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma.
  • PATIENTS AND METHODS: Two hundred ninety-four patients with untreated stage IV metastatic melanoma (American Joint Committee on Cancer staging system) were randomly assigned to receive either oral TMZ alone (200 mg/m2/day; days 1 through 5 every 28 days) or in combination with subcutaneous IFN-alpha (5 MU/m2; days 1, 3, and 5 every week).
  • In the TMZ + IFN-alpha arm, 33 (24.1%) of 137 patients responded to therapy (partial or complete remission) whereas in the monotherapy arm, in 18 (13.4%) of 134 patients, a response was evident.
  • Thus, the response rate was significantly higher in the combination arm (P = .036).
  • Dose modifications and interval prolongations due to hematologic toxicity were significantly more frequent in the TMZ + IFN-alpha arm (P < .001).
  • CONCLUSION: In metastatic melanoma treatment with TMZ + IFN-alpha leads to a significantly superior OR rate compared to treatment with TMZ alone, which did not translate into prolonged survival in our study population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


57. Stang A, Pukkala E, Sankila R, Söderman B, Hakulinen T: Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer; 2006 Jul 15;119(2):380-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases.
  • Site-specific analyses of the skin melanoma incidence show marked differences between men and women by site and over time.
  • The aim of our study was to analyze long-term population-based incidence time trends of skin melanoma in Finland over a period of more than 50 years, with special emphasis on sex- and subsite-specific changes over time.
  • From 1953 through 2003, the incidence of skin melanoma increased from 1.5 to 12.8 per 100,000 among men and from 1.8 to 10.4 per 100,000 among women.
  • Within the skin area of the head, melanoma of the ear showed the highest relative increase among both men and women.
  • Only skin melanoma of the head showed an exponential age-specific incidence pattern and the aetiology of these skin melanomas may differ from skin melanoma on other subsites.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Arm. Back. Female. Finland / epidemiology. Head. Hip. Humans. Incidence. Leg. Male. Middle Aged. Sex Distribution. Sex Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477634.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Kim JY, Ross MI, Butler CE: Reconstruction following radical resection of recurrent metastatic axillary melanoma. Plast Reconstr Surg; 2006 Apr 15;117(5):1576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction following radical resection of recurrent metastatic axillary melanoma.
  • BACKGROUND: Recurrent axillary metastasis following axillary lymphadenectomy for melanoma is associated with a poor prognosis.
  • METHODS: A retrospective review of all patients who underwent axillary reexcision and reconstruction for metastatic melanoma between 1990 and 2000 was conducted at The University of Texas M. D.
  • [MeSH-major] Melanoma / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Arm / surgery. Axilla. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Surgical Mesh. Treatment Outcome


59. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, Rovere-Querini P: The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol; 2006 Jul;80(1):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pentraxins (PTX) and complement belong to the humoral arm of the innate immune system and have essential functions in immune defense to microbes and in scavenging cellular debris.
  • Moreover, PTX3 inhibited the cross-presentation of the MELAN-A/melanoma antigen-reactive T cell 1 (MART-1) tumor antigen expressed by dying cells, even in the presence of C1q.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617159.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP05095
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / Serum Amyloid P-Component; 148591-49-5 / PTX3 protein; 80295-33-6 / Complement C1q; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


60. van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, Brüggenwirth HT, van Ijcken W, Paridaens D, Luyten GP, de Klein A: Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci; 2008 Oct;49(10):4254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
  • PURPOSE: Although studies on uveal melanoma (UM) revealed prognostic significance of chromosomal aberrations, they resulted in classification errors in survival prediction.
  • A locally adaptive statistical procedure identified two regions on the short arm of chromosome 3 with decreased gene-expression in tumors with shorter disease-free survival.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / physiology. Melanoma / genetics. Oligonucleotide Array Sequence Analysis. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552379.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Radfar A, Stefanato CM, Ghosn S, Bhawan J: NGFR-positive desmoplastic melanomas with focal or absent S-100 staining: Further evidence supporting the use of both NGFR and S-100 as a primary immunohistochemical panel for the diagnosis of desmoplastic melanomas. Am J Dermatopathol; 2006 Apr;28(2):162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic diagnosis of desmoplastic melanoma can be challenging in circumstances in which biopsy specimens are small, or there are unsuspected clinical settings, re-excision scars, and unusual sites.
  • In addition, NGFR, a marker of Schwannian differentiation, has been shown to be a useful confirmatory stain for desmoplastic melanoma, with staining intensity comparable with, or better than that of S-100 protein.
  • [MeSH-major] Melanoma / pathology. Nerve Tissue Proteins / analysis. Receptors, Nerve Growth Factor / analysis. S100 Proteins / analysis. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Arm / pathology. Biomarkers, Tumor / analysis. Female. Humans. Hutchinson's Melanotic Freckle / pathology. Immunohistochemistry. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625082.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor; 0 / S100 Proteins
  •  go-up   go-down


62. Mowbray M, Stockton DL, Doherty VR: Changes in the site distribution of malignant melanoma in South East Scotland (1979-2002). Br J Cancer; 2007 Mar 12;96(5):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the site distribution of malignant melanoma in South East Scotland (1979-2002).
  • Scottish Melanoma Group (SMG) data on 2790 melanoma (MM) cases in South East Scotland over a 24-year time period were analysed in four periods each of 6 years duration grouped into frequently exposed, intermittently exposed, and always covered sites.
  • In both sexes, the proportion of cases seen on the posterior trunk and arm increased significantly (P<0.001), but declines were seen in the proportion of leg tumours in males (P=0.09) and of head tumours in females (P=0.011).
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):380-4 [16477634.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):627-32 [10699940.001]
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):416-23 [10869312.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):457-62 [11291086.001]
  • [Cites] Lancet. 2002 Aug 24;360(9333):587-91 [12241928.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):483-9 [1995477.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):232-6 [8425760.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):341-50 [8080946.001]
  • [Cites] Health Rep. 1998 Autumn;10(2):29-41 (Eng); 33-46 (Fre) [9842489.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):407-16 [10530611.001]
  • [Cites] Am J Epidemiol. 1990 Dec;132(6):1066-77 [2260538.001]
  • (PMID = 17299392.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360061
  •  go-up   go-down


63. Grünhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol; 2005 Nov;31(9):1011-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Isolated limb perfusion with TNF and melphalan (TM-ILP) is highly effective in the local treatment of advanced sarcoma and melanoma of the limb.
  • Out of 339 TM-ILPs performed between 1991 and 2003, 64 procedures were performed with reduced TNF dose (<3 mg in arm perfusions, <4 mg in leg perfusions).
  • RESULTS: Complete response in melanoma patients after reduced-dose ILP was 75 vs 69% after standard-dose ILPs (overall response 94 vs 95%, respectively); overall response in non-melanoma patients was 69 (reduced) vs 74% (standard).
  • Response rates and outcome were comparable with the procedures performed with standard-dose TNF (p=NS for response, local/systemic progression and survival after multivariate analysis, both in melanoma and in non-melanoma patients).
  • CONCLUSION: Provided doses at 1mg or higher are used, TM-ILP with TNF dose reduction for both melanoma and non-melanoma patients seems to be as effective as the standard dose procedure in terms of response rate and patient outcome.
  • [MeSH-major] Arm. Chemotherapy, Cancer, Regional Perfusion. Leg. Melanoma / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099618.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


64. Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol; 2006 Dec 20;24(36):5716-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
  • We performed an open-label, multicenter, single-arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients.
  • PATIENTS AND METHODS: Patients with unresectable stage IIIb/c or stage IV melanoma received 6 mg PF-3512676 weekly by subcutaneous injection for 24 weeks or until disease progression to evaluate safety as well as clinical and immunologic activity.
  • [MeSH-major] Melanoma / therapy. Oligonucleotides / therapeutic use. Skin Neoplasms / therapy. Toll-Like Receptor 9 / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Type I; 0 / Oligonucleotides; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9
  •  go-up   go-down


65. Thomas JM: Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg; 2009 Apr;62(4):442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma.
  • The first Multicenter Selective Lymphadenectomy Trial (MSLT-I) was designed to test for a survival difference following wide excision of primary melanoma between patients randomised to sentinel lymph node biopsy (SLNB) and early lymphadenectomy when metastatic disease was identified (the biopsy arm) versus observation alone and delayed lymphadenectomy when regional lymph nodes became palpable (the observation arm).
  • Contrary to that stated in the protocol, almost half the patients entered to the observation arm of MSLT-I were investigated by lymphoscintigraphy and regular targeted high-resolution ultrasound which detected nodal metastasis in some patients before it became palpable, thus influencing the primary end-point of the trial.
  • Patients with melanoma die of distant metastatic spread and currently there is no evidence that the SLNB procedure influences distant disease-free survival.
  • [MeSH-major] Lymph Node Excision. Melanoma / secondary. Melanoma / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246272.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 13
  •  go-up   go-down


66. Kirsch A: Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Altern Complement Med; 2007 May;13(4):443-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M).
  • BACKGROUND: Recent study results demonstrate possible clinical benefit from adjuvant treatment with a standardized mistletoe (Viscum album) extract in patients with malignant melanoma.
  • PATIENT AND METHOD: We present a male patient, currently 68 years of age, with one malignant melanoma at the upper part of the right arm since 1992, and another nodular melanoma at the left shoulder, first diagnosed in 1999.
  • After discovery of the second melanoma and surgical resection, the patient was exclusively treated with standardized mistletoe extract (Iscador, (R)M; Weleda AG, CH-Arlesheim, Switzerland).
  • COURSE OF THERAPY AND RESULTS: In June 1992, histologic analysis confirmed the presence of stage IA superficially spreading malignant melanoma with low infiltration of the papillary dermis in a skin excision sample from the upper part of the right arm.
  • In November 1999, another melanoma was surgically removed at the patient's right shoulder.
  • In this case, the histologic examination revealed nodular melanoma, stage IIA (pT3, pN0, M0).
  • CONCLUSIONS: The use of low-dose Iscador as the sole postoperative modality for the adjuvant treatment of metastatic melanoma was extremely effective and very well tolerated in this patient.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Melanoma / secondary. Plant Extracts / administration & dosage. Plant Proteins / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532738.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 0 / Antineoplastic Agents; 0 / Plant Extracts; 0 / Plant Proteins; 0 / viscum album peptide
  •  go-up   go-down


67. O'Neill PA, Butt M, Eswar CV, Gillis P, Marshall E: A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res; 2006 Jun;16(3):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
  • Uveal melanoma is relatively uncommon accounting for fewer than 5% of all melanoma cases.
  • Uncertainty remains concerning the level of activity of dacarbazine in uveal melanoma as opposed to that in the cutaneous form.
  • A phase II study was therefore undertaken to assess the objective response rate of the combination of dacarbazine and treosulfan in previously untreated patients with metastatic uveal melanoma.
  • This study, using the combination of dacarbazine and treosulfan, while well tolerated, did not confirm earlier reports suggesting treosulfan is active in uveal melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Uveal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718271.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan
  •  go-up   go-down


68. Ito M, Ogawa J: [Sentinel lymph node mapping in non-small cell lung cancer]. Kyobu Geka; 2009 Jul;62(8 Suppl):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SN mapping and biopsy were developed as techniques for staging the lymphatic basin without the potential morbidity of lymph edema and nerve injury in cases of melanoma, or lymph edema of the arm in cases of breast cancer.


69. Collaborative Ocular Melanoma Study Group: Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27. Ophthalmology; 2007 Jul;114(7):1363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.
  • PURPOSE: To evaluate the effect of the radiation dose to the lens on cataract formation and effect of cataract surgery on visual acuity (VA) among patients with choroidal melanoma treated with iodine 125 (I125) brachytherapy.
  • DESIGN: Prospective study of patients enrolled in one arm of a randomized clinical trial.
  • PARTICIPANTS: Patients enrolled in the Collaborative Ocular Melanoma Study (COMS) who received I125 brachytherapy as randomly assigned and also were phakic, with no history of cataract in the study eye at the time of enrollment (n = 532).
  • [MeSH-major] Brachytherapy / adverse effects. Cataract / epidemiology. Cataract / etiology. Cataract Extraction / adverse effects. Choroid Neoplasms / radiotherapy. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / adverse effects. Melanoma / radiotherapy

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Cataract.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337065.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00000124
  • [Grant] United States / NEI NIH HHS / EY / EY6253; United States / NEI NIH HHS / EY / EY6257; United States / NEI NIH HHS / EY / EY6259; United States / NEI NIH HHS / EY / EY6260; United States / NEI NIH HHS / EY / EY6264; United States / NEI NIH HHS / EY / EY6265; United States / NEI NIH HHS / EY / EY6266; United States / NEI NIH HHS / EY / EY6268; United States / NEI NIH HHS / EY / EY6269; United States / NEI NIH HHS / EY / EY6270; United States / NEI NIH HHS / EY / EY6274; United States / NEI NIH HHS / EY / EY6275; United States / NEI NIH HHS / EY / EY6276; United States / NEI NIH HHS / EY / EY6279; United States / NEI NIH HHS / EY / EY6280; United States / NEI NIH HHS / EY / EY6282; United States / NEI NIH HHS / EY / EY6283; United States / NEI NIH HHS / EY / EY6284; United States / NEI NIH HHS / EY / EY6287; United States / NEI NIH HHS / EY / EY6288; United States / NEI NIH HHS / EY / EY6289; United States / NEI NIH HHS / EY / EY6291; United States / NEI NIH HHS / EY / EY6839; United States / NEI NIH HHS / EY / EY6843; United States / NEI NIH HHS / EY / EY6848; United States / NEI NIH HHS / EY / EY6858; United States / NEI NIH HHS / EY / EY6899
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


70. Mahé E, Beauchet A, Aegerter P, Saiag P: Neonatal blue-light phototherapy does not increase nevus count in 9-year-old children. Pediatrics; 2009 May;123(5):e896-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: One of the most important risk factors for melanoma is the number of acquired common and atypical nevi in childhood.
  • We counted back and arm nevi as a function of size in 828 children included in a French photoprotection educational campaign.

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403483.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Danino AM, Kadlub N, Dalac S, Boichot C, Malka G: Reducing the number of sentinel nodes removed in melanoma patients: a prospective study. Indian J Cancer; 2006 Jul-Sep;43(3):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing the number of sentinel nodes removed in melanoma patients: a prospective study.
  • CONTEXT: Since 1992, sentinel lymph node (SLN) biopsy was generally applied to melanoma for tumor staging.
  • MATERIALS AND METHODS: We conducted a single-arm prospective study in patients with stage I melanoma.
  • We analyzed the characteristics of each melanoma, the success rate of this procedure, how many nodes were removed and how many had micro metastases.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065772.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


72. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G, DC study group of the DeCOG: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol; 2006 Apr;17(4):563-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
  • BACKGROUND: This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients.
  • RESULTS: At the time of the first interim analysis 55 patients had been enrolled into the DTIC and 53 into the DC-arm (ITT).
  • Only in the DC-arm did those patients with (i) an initial unimpaired general health status (Karnofsky = 100) or (ii) an HLA-A2+/HLA-B44- haplotype survive significantly longer than patients with a Karnofsky index <100 (P = 0.007 versus P = 0.057 in the DTIC-arm) or other HLA haplotypes (P = 0.04 versus P = 0.57 in DTIC-treated patients).
  • CONCLUSIONS: DC vaccination could not be demonstrated to be more effective than DTIC chemotherapy in stage IV melanoma patients.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2006 Apr;17(4):539-41 [16556849.001]
  • (PMID = 16418308.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Peptides; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


73. Ahmadi N, Davison SP, Kauffman CL: Melanocytic nevi with Spitz differentiation: diagnosis and management. Laryngoscope; 2010 Dec;120(12):2385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distinct entities include Spitz nevus, atypical Spitz nevus, and Spitzoid melanoma.
  • Their histopathologic differentiation can be challenging, and cases of Spitzoid melanoma initially diagnosed as benign Spitz nevi are reported in the literature.
  • The goal of this article is to discuss the diagnostic tools (including comparative genomic hybridization), which may be helpful in differentiating benign Spitz nevi from malignant melanoma with Spitzoid features, and to propose an appropriate management strategy for each entity.
  • [MeSH-minor] Adult. Arm. Back. Biopsy. Cell Differentiation. Child. Child, Preschool. Dermis / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072755.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H: Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2005 Jun;16(6):950-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
  • We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma.
  • RESULTS: Tumor responses (complete and partial responses) were seen in 16 patients (26%) in arm A and 19 patients (29%) in arm B.
  • The median time to progression (TTP) was 3.8 months in arm A and 5.8 months in arm B.
  • The median overall survival (OS) was 11.5 months in arm A and 12 months in arm B.
  • There was significantly more grade 3 and 4 emesis in the combination arm.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829494.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


75. Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F: Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol; 2007 Apr;18(4):789-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series.
  • BACKGROUND: The relation between detailed cutaneous distribution of melanoma and indicators of sun exposure patterns has scantily been explored in moderately sun-sensitive populations.
  • PATIENTS AND METHODS: The precise site of 1658 primary malignant melanoma, registered from 1995 to 2002, in Switzerland were retrieved and clinically validated.
  • Relative melanoma density (RMD) was computed by the ratio of observed to expected number of melanoma allowing for body site surface areas, and further adjusted for site-specific melanocyte density.
  • RESULTS: Sites of highest risks were the face, shoulder and upper arm for both sexes, the back for men, and leg for women.
  • Major features of this series were: (i) an unexpectedly high RMD for the face in women (5.6 versus 3.7 in men), (ii) the absence of a male predominance for melanoma on the ears and (iii) for the upper limbs, a steady gradient of increasing melanoma density with increasing proximity to the trunk, regardless of sex.
  • CONCLUSION: RMD increased with (cumulative) site sun exposure, but a few notable exceptions support the impact of intermittent exposure in melanoma risk.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237475.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Sendi P, Puric E, Schönenberger A, Bargetzi M: [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. Praxis (Bern 1994); 2007 May 2;96(18):729-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
  • [Transliterated title] Chronische lymphatische Leukämie und Kraftverlust im rechten Arm--eine nicht typische Kombination.
  • In addition some forms of tumors, such as Kaposi sarkoma, malignant melanoma, laryngeal carcinoma, lung cancer and Hodgkin Lymphoma are found more frequently in this patient population.
  • [MeSH-minor] Administration, Oral. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arm. Benzenesulfonates / administration & dosage. Benzenesulfonates / therapeutic use. Bone Neoplasms / secondary. Clinical Trials, Phase III as Topic. Disease Progression. Humans. Hypesthesia / etiology. Indoles / administration & dosage. Indoles / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Muscle Weakness / etiology. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / therapeutic use. Pyridines / administration & dosage. Pyridines / therapeutic use. Pyrroles / administration & dosage. Pyrroles / therapeutic use. Radiography, Abdominal. Radiography, Thoracic. Risk. Risk Factors. Sex Factors. Splenic Neoplasms / secondary. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520841.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


77. Mensink HW, Kiliç E, Vaarwater J, Douben H, Paridaens D, de Klein A: Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. Cancer Genet Cytogenet; 2008 Mar;181(2):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome.
  • Uveal melanoma (UM) is the most common primary intraocular tumor in the Western world.
  • In 44 tumors aberrations were present and classic prognostic markers as loss of 1p (12 tumors, 26.1%), monosomy 3 (26 tumors, 56.5%), loss of 6q (10 tumors, 21.7%), and gain of chromosome arm 8q (27 tumors, 58.7%) were observed.
  • [MeSH-major] Chromosome Aberrations. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295662.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol; 2009 Jul 01;27(19):3133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In each arm, 12 patients who received 0 to 1 prior lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor).
  • This was the only arm to meet the RECIST response rate primary end point.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Oct;47(10):853-9 [18615679.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3586-91 [12202658.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):623-6 [12209598.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):641-5 [8264632.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):138-44 [7828144.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28834-8 [7499408.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):866-73 [15681532.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] Cancer J. 2005 May-Jun;11(3):241-7 [16053668.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):706-11 [16496406.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2023-9 [17404082.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2643-50 [17473195.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7106-12 [17671177.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):361-7 [18202410.001]
  • [Cites] Curr Treat Options Oncol. 2007 Dec;8(6):428-34 [18066504.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):821-2 [18296418.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):890-6 [18413802.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2717-25 [18451237.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • (PMID = 19451436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62202; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2716936
  •  go-up   go-down


79. Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Morton DL, MSLT Cooperative Group: The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol; 2010 Dec;17(12):3324-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).
  • BACKGROUND: Complete lymph node dissection, the current standard treatment for nodal metastasis in melanoma, carries the risk of significant morbidity.
  • MATERIALS AND METHODS: The Multicenter Selective Lymphadenectomy Trial I randomized patients to wide excision of a primary melanoma with or without sentinel lymph node biopsy.
  • Immediate completion lymph node dissection (early CLND) was performed when indicated in the SLN arm, while therapeutic dissection (delayed CLND) was performed at the time of clinical recurrence in the wide excision-alone arm.
  • RESULTS: Early CLND was performed in 225 patients, and in the wide excision-alone arm 132 have undergone delayed CLND.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):339-51 [12229941.001]
  • [Cites] Ann Surg Oncol. 2010 Mar;17(3):731-7 [20183910.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):676-80 [12839853.001]
  • [Cites] Tumori. 1984 Dec 31;70(6):529-33 [6531796.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Am J Surg. 1992 Nov;164(5):462-5; discussion 465-6 [1443370.001]
  • [Cites] Ann Surg Oncol. 1999 Apr-May;6(3):255-62 [10340884.001]
  • [Cites] Arch Surg. 2005 Jan;140(1):85-9 [15655211.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3 [16135917.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):87-91 [16425311.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] Surgery. 2007 Jun;141(6):728-35 [17560249.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3530-5 [18640934.001]
  • [Cites] Acta Chir Belg. 2008 Nov-Dec;108(6):685-90 [19241918.001]
  • [Cites] Cancer Control. 2009 Jul;16(3):240-7 [19556964.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2840-7 [19639366.001]
  • [CommentIn] Ann Surg Oncol. 2011 Feb;18(2):306-8 [21161723.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S311; author reply S312-4 [21773841.001]
  • (PMID = 20614193.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA029605-29; United States / NCI NIH HHS / CA / P01 CA029605; United States / NCI NIH HHS / CA / CA29605; United States / NCI NIH HHS / CA / P01 CA029605-29
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216768; NLM/ PMC2970739
  •  go-up   go-down


80. Vukomanovic P, Karanikolic A, Stefanoviic M, Mihajlovic D, Djordjevic B, Kutlesic R: Late recurrence of malignant melanoma mimicking ovarian malignancy. Eur J Gynaecol Oncol; 2010;31(5):590-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence of malignant melanoma mimicking ovarian malignancy.
  • BACKGROUND: Malignant melanoma (MM) is an extremely malignant tumor with an unpredictable profile of spread and variable periods of remission.
  • CASE: We describe an unusual case of malignant melanoma metastatic to the omentum occurring seven years after diagnosis and treatment of cutaneous malignant melanoma in the patient's arm.
  • To date, nine months after detection of malignant melanoma metastatic to the omentum, the patient is alive with no clinical and radiological metastatic disease.
  • CONCLUSIONS: The diagnosis of omentum malignant melanoma in a living patient is uncommon, thus very few individuals and referral centers can build up an adequate experience of handling this disease.
  • [MeSH-major] Melanoma / secondary. Omentum / pathology. Ovarian Neoplasms / ultrasonography. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / ultrasonography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061811.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J: A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol; 2007 Jan;59(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a dose-escalating, single arm, prospective, open label, non-randomised phase I trial of epirubicin (75 mg/m(2)) in combination with escalating oral doses of sulindac (0-800 mg) in patients with advanced cancer to identify an appropriate dose of sulindac to use in future resistance studies.
  • RESULTS: Seventeen patients (8 breast, 3 lung, 2 bowel, 1 melanoma, 1 renal, 1 ovarian and 1 of unknown primary origin, 16/17 having had prior chemotherapy) were enrolled.
  • Among 15 patients with evaluable tumour, two partial responses were seen (malignant melanoma and breast cancer).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642371.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibiotics, Antineoplastic; 0 / P-Glycoprotein; 0 / Troponin; 184SNS8VUH / Sulindac; 3Z8479ZZ5X / Epirubicin; AYI8EX34EU / Creatinine
  •  go-up   go-down


82. Roller E, Ruzicka T, Schulte KW: [Subclavian thrombosis after port system implantation]. Hautarzt; 2007 Jan;58(1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a patient with metastatic malignant melanoma, who developed a deep arm vein thrombosis two weeks after port implantation.
  • The prognosis of deep arm vein thrombosis is determined by the development of pulmonary embolism (8-36%).
  • [MeSH-minor] Humans. Male. Melanoma / complications. Melanoma / secondary. Melanoma / therapy. Middle Aged. Radiography. Skin Neoplasms / complications. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Circulation. 2002 Oct 1;106(14):1874-80 [12356644.001]
  • [Cites] Palliat Med. 2005 Apr;19(3):197-201 [15920933.001]
  • [Cites] J Ultrasound Med. 2005 Jun;24(6):829-38; quiz 839-40 [15914687.001]
  • [Cites] Thromb Res. 1997 Apr 15;86(2):101-13 [9175232.001]
  • [Cites] Ann Vasc Surg. 2004 Sep;18(5):552-7 [15534734.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):507-12 [14617015.001]
  • [Cites] Presse Med. 1952 Oct 25;60(68):1456 [13027062.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1586-9 [6616416.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):456-8 [11853785.001]
  • [Cites] Surg Gynecol Obstet. 1973 Apr;136(4):602-6 [4632149.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2253-9 [15454250.001]
  • [Cites] Blood Coagul Fibrinolysis. 2005 Oct;16(7):517-23 [16175012.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):137-45 [10357081.001]
  • [Cites] Am J Surg. 2004 Dec;188(6):722-7 [15619490.001]
  • [Cites] Hamostaseologie. 2004 May;24(2):144-6 [15136879.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):596-600 [15961840.001]
  • [Cites] J Vasc Interv Radiol. 2002 Feb;13(2 Pt 1):179-84 [11830624.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1263-74 [14991322.001]
  • [Cites] Vasa. 1999 May;28(2):71-8 [10409916.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):61-6 [15999349.001]
  • [Cites] Dtsch Med Wochenschr. 2000 May 19;125(20):628-30 [11256046.001]
  • [Cites] Surg Gynecol Obstet. 1979 Jun;148(6):871-5 [109934.001]
  • [Cites] Intern Med J. 2002 Mar;32(3):84-8 [11885848.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):235-41 [14760527.001]
  • (PMID = 16523279.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Kilic E, van Gils W, Lodder E, Beverloo HB, van Til ME, Mooy CM, Paridaens D, de Klein A, Luyten GP: Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci; 2006 Sep;47(9):3703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic analyses in uveal melanoma.
  • PURPOSE: Uveal melanoma is one of the most frequently occurring primary intraocular malignancies in the Western world.
  • The most frequent chromosomal abnormalities involved chromosome 8 (53%); loss of chromosome 3, p-arm (41%) and q-arm (42%); partial loss of chromosome 1, p-arm (24%); and abnormalities in chromosome 6 that resulted in gain of 6p (18%) and/or loss of 6q (28%).
  • Less-frequent aberrations were abnormalities in chromosome 16, in particular loss of chromosome 16 q-arm (16%).
  • CONCLUSIONS: Monosomy 3 and largest tumor diameter are the most significant in determining survival of patients with uveal melanoma.
  • Abnormalities in the q-arm of chromosome 16 are relatively common in uveal melanoma, but are not associated with survival or other cytogenetic or histopathologic parameters.
  • [MeSH-major] Chromosome Aberrations. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936076.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M: A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs; 2007 Jun;25(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
  • There is no effective systemic therapy for disseminated metastatic melanoma.
  • Data suggest that endothelin may play a role in pathophysiology of melanoma and that the dual endothelin receptor antagonist bosentan may have anti-tumor activity.
  • This multicenter, open-label, single-arm, prospective, proof-of-concept study assessed the effects of bosentan monotherapy (500 mg oral tablets, bid) on tumor response in patients with stage IV metastatic melanoma.
  • Among the 35 patients included in this study with stage IV metastatic melanoma, 21 (60%) were stage M1C, 10 (29%) stage M1B and 4 (11%) stage M1A (American Joint Committee on Cancer [AJCC] classification).
  • Nine patients (26%) had received prior therapy for stage IV melanoma.
  • Bosentan might have benefit in disease stabilization in certain patients with metastatic melanoma and deserves further investigation in combination with other anticancer drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endothelin Receptor Antagonists. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1135-9 [15610525.001]
  • [Cites] J Card Fail. 2005 Feb;11(1):12-20 [15704058.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1118-25 [15020614.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):443-52 [12189238.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):32-7 [7615973.001]
  • [Cites] Hum Mol Genet. 1995 Nov;4(11):2089-96 [8589685.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1436-43 [14973117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7 [8632985.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1267-76 [8001159.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2243-78 [15589643.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):182-7 [10738244.001]
  • [Cites] Virchows Arch. 2001 May;438(5):485-91 [11407477.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1277-85 [8001160.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1681-9 [11092528.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Vasc Res. 2001 Nov-Dec;38(6):536-45 [11740152.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9 [16741059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 [10500205.001]
  • (PMID = 17021960.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin Receptor Antagonists; 0 / RNA, Messenger; 0 / Receptors, Endothelin; 0 / Sulfonamides; 0 / Tablets; Q326023R30 / bosentan
  •  go-up   go-down


85. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G: Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res; 2009 Mar 15;15(6):2123-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
  • We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma.
  • EXPERIMENTAL DESIGN: Open-label, single-arm, two-stage trial.
  • ELIGIBILITY CRITERIA: unresectable metastatic melanoma, measurable disease by Response Evaluation Criteria in Solid Tumors, no prior systemic therapy (adjuvant IFN permitted), adequate major organ function, good performance status, no significant autoimmune disease, and life expectancy at least 4 months.
  • CONCLUSIONS: rIL-21 administered at 30 microg/kg/d in 5-day cycles every second week is biologically active and well tolerated in patients with metastatic melanoma.
  • [MeSH-major] Interleukins / therapeutic use. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276257.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukins; 0 / Recombinant Proteins; 0 / interleukin-21
  •  go-up   go-down


86. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM: Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res; 2007 Jun;17(3):193-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
  • In patients with stage IIB-III disease, adjuvant high-dose interferon-alpha2b has shown clinical benefit, although metastatic melanoma is currently without any known survival-prolonging therapy.
  • Angiogenesis has been considered important in melanoma progression, and endostatin is an angiogenesis inhibitor with antitumor activity that has shown promising results in murine model systems, prompting investigation of a formulation of rh-Endostatin (EntreMed, Rockville, Maryland, USA) alone and with interferon in metastatic melanoma.
  • Patients were randomly assigned to receive interferon alpha2b (Schering-Plough) 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A) vs. rh-Endostatin alone (arm B).
  • Basic fibroblast growth factor levels in urine were significantly lower following treatment in patients on arm B (P=0.043).
  • Low titer (<or=1:25) IgG antibodies against the rh-Endo formulation were detected in two patients (one per arm) in cycle 4.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505265.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / P30 CA4790413
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


87. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S: Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer; 2009 Sep 1;115(17):3944-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
  • BACKGROUND: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study.
  • RESULTS: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone.
  • Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm.
  • [MeSH-major] Dacarbazine / administration & dosage. Melanoma / drug therapy. Oligodeoxyribonucleotides / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536884.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


88. Yoshida Y, Takahashi A, Koga M, Koga K, Kubota Y, Nakayama J: Case of metastatic melanoma in an epitrochlear lymph node arising in a pregnant woman. J Dermatol; 2007 Jan;34(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of metastatic melanoma in an epitrochlear lymph node arising in a pregnant woman.
  • We describe a rare case of metastatic melanoma in an epitrochlear lymph node in a 29-year-old female patient.
  • Histological examination revealed a malignant melanoma.
  • We emphasize that it is important for clinicians to pay attention to the possibility of epitrochlear node metastasis in patients with malignant melanoma in the upper extremity and that it is necessary to perform sentinel node biopsy to identify uncommon lymph node metastasis.
  • [MeSH-major] Melanoma / secondary. Pregnancy Complications, Neoplastic. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Arm. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Pregnancy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204101.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Quirt I, Verma S, Petrella T, Bak K, Charette M: Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist; 2007 Sep;12(9):1114-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for the treatment of metastatic melanoma: a systematic review.
  • BACKGROUND: This systematic review examines the role of temozolomide in patients with metastatic melanoma.
  • METHODS: The MEDLINE, EMBASE, and Cochrane Library databases were searched from 1980 through to 2005 using variations on the search terms: melanoma, clinical trial, random, temozolomide, temodal, and temodar.
  • A second phase III study comparing single-agent temozolomide with temozolomide combined with interferon-alpha indicated a significantly higher response rate for the combination treatment arm, but no difference in overall survival was noted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Melanoma / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914081.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 36
  •  go-up   go-down


90. Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol; 2006 Dec;124(12):1684-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.
  • OBJECTIVES: To report refined rates of death and related outcomes by treatment arm through 12 years after primary treatment of choroidal melanoma and to evaluate characteristics of patients and tumors as predictors of relative treatment effectiveness and time to death.
  • DESIGN: Randomized multicenter clinical trial of iodine 125 ((125)I) brachytherapy vs enucleation conducted as part of the Collaborative Ocular Melanoma Study.
  • Decedents were classified by the independent Mortality Coding Committee as having histopathologically confirmed melanoma metastasis, suspected melanoma metastasis without histopathologic confirmation, another cancer but not melanoma metastasis, or no malignancy.
  • MAIN OUTCOME MEASURES: Deaths from all causes and deaths with histopathologically confirmed melanoma metastasis.
  • For patients in both treatment arms, 5- and 10-year all-cause mortality rates were 19% and 35%, respectively; by 12 years, cumulative all-cause mortality was 43% among patients in the (125)I brachytherapy arm and 41% among those in the enucleation arm.
  • Five-, 10-, and 12-year rates of death with histopathologically confirmed melanoma metastasis were 10%, 18%, and 21%, respectively, in the (125)I brachytherapy arm and 11%, 17%, and 17%, respectively, in the enucleation arm.
  • Older age and larger maximum basal tumor diameter were the primary predictors of time to death from all causes and death with melanoma metastasis.
  • APPLICATION TO CLINICAL PRACTICE: Estimated mortality rates by baseline characteristics should facilitate counseling of patients who have choroidal melanoma of a size and in a location suitable for enucleation or (125)I brachytherapy and no evidence of metastasis or another malignancy.
  • [MeSH-major] Brachytherapy / methods. Choroid Neoplasms / mortality. Choroid Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Melanoma / mortality. Melanoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159027.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00000124
  • [Grant] United States / NEI NIH HHS / EY / EY06253; United States / NEI NIH HHS / EY / EY06257; United States / NEI NIH HHS / EY / EY06258; United States / NEI NIH HHS / EY / EY06260; United States / NEI NIH HHS / EY / EY06264; United States / NEI NIH HHS / EY / EY06265; United States / NEI NIH HHS / EY / EY06266; United States / NEI NIH HHS / EY / EY06268; United States / NEI NIH HHS / EY / EY06269; United States / NEI NIH HHS / EY / EY06270; United States / NEI NIH HHS / EY / EY06274; United States / NEI NIH HHS / EY / EY06275; United States / NEI NIH HHS / EY / EY06276; United States / NEI NIH HHS / EY / EY06279; United States / NEI NIH HHS / EY / EY06280; United States / NEI NIH HHS / EY / EY06282; United States / NEI NIH HHS / EY / EY06283; United States / NEI NIH HHS / EY / EY06284; United States / NEI NIH HHS / EY / EY06287; United States / NEI NIH HHS / EY / EY06288; United States / NEI NIH HHS / EY / EY06289; United States / NEI NIH HHS / EY / EY06291; United States / NEI NIH HHS / EY / EY06839; United States / NEI NIH HHS / EY / EY06843; United States / NEI NIH HHS / EY / EY06844; United States / NEI NIH HHS / EY / EY06848; United States / NEI NIH HHS / EY / EY06858; United States / NEI NIH HHS / EY / EY06899
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


91. Damian DL, Barnetson RS, Thompson JF: Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg; 2006 Jan-Feb;10(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A man developed extensive chromomycosis of the left arm, refractory to multiple systemic and local treatments.
  • Regional chemotherapy with the isolated limb infusion (ILI) technique using melphalan and actinomycin D markedly reduced disease bulk and greatly improved function of the arm over the next 2 months.
  • [MeSH-major] Arm. Chromoblastomycosis / drug therapy. Dactinomycin / therapeutic use. Melphalan / therapeutic use. Perfusion / methods

  • Genetic Alliance. consumer health - Chromomycosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241574.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; Q41OR9510P / Melphalan
  •  go-up   go-down


92. Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C: Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of &gt;= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol; 2010 Feb 10;28(5):841-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
  • PURPOSE Low-dose (LD) interferon (IFN) alfa (LDI) has demonstrated a consistent disease-free survival benefit for patients with clinically lymph node-negative melanoma in clinical trials.
  • A prolongation of LDI from 18 months to 60 months might be of clinical benefit for patients with intermediate or high-risk melanoma.
  • PATIENTS AND METHODS Eight hundred fifty patients with resected cutaneous melanoma of at least 1.5 mm tumor thickness were included in this prospective randomized, multicenter trial in Germany and Austria.
  • They were randomly assigned to receive 3 MU IFNalpha2a three times a week subcutaneously for either 18 months (arm A) or 60 months (arm B).
  • SLNB was performed in 635 patients (75.6%), with a positivity rate of 18.0% in arm A and 17.5% in arm B.
  • Neither relapse-free survival (arm A, 75.6% v arm B, 72.6%; P = .72; hazard ratio, 1.05; 95% CI, 0.80 to 1.39) nor distant-metastasis-free survival (81.9% v 79.7%; P = .56; HR, 1.10; 95% CI, 0.80 to 1.52) or overall survival (85.9% v 84.9%; P = .86; HR, 1.03; 95% CI, 0.71 to 1.50) showed significant differences.
  • CONCLUSION A prolongation of conventional LDI therapy from 18 to 60 months showed no clinical benefit in patients with intermediate and high-risk primary melanoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048184.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


93. Knorr C, Melling N, Goehl J, Drachsler T, Hohenberger W, Meyer T: Long-term functional outcome after hyperthermic isolated limb perfusion (HILP). Int J Hyperthermia; 2008 Aug;24(5):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: One of the biological characteristics of melanoma is the locoregional development of metastases that are difficult to treat by conventional tumour mass reduction.
  • Locoregionally metastasised melanoma of the limb can effectively be treated by hyperthermic isolated limb perfusion (HILP).
  • MATERIALS AND METHODS: 312 patients with melanoma of the limb underwent HILP in our department between 1977 and 1983.
  • The other examination results showed no significant differences in comparison to the healthy arm.
  • Response rates and results of HILP have greatly improved in the last years due to numerous modifications so that this treatment is the method of choice in locoregionally metastasised melanoma of the limb in spite of the long-term complication rate.
  • [MeSH-major] Arm. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Leg. Melanoma / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608587.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Berg LC, Mata X, Thomsen PD: Molecular characterization and chromosomal assignment of equine cartilage derived retinoic acid sensitive protein (CD-RAP)/melanoma inhibitory activity (MIA). Gene; 2008 Jan 15;407(1-2):98-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization and chromosomal assignment of equine cartilage derived retinoic acid sensitive protein (CD-RAP)/melanoma inhibitory activity (MIA).
  • Cartilage-derived retinoic acid sensitive protein (CD-RAP) also known as melanoma inhibitory activity (MIA) has already been established as a marker for chondrocyte differentiation and a number of cancerous conditions in humans.
  • Using radiation hybrid mapping, the CD-RAP/MIA gene was localized to the p arm of equine chromosome 10 (ECA10p), which is in accordance with prediction based on the current human-equine comparative map.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977671.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF679787
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 5688UTC01R / Tretinoin
  •  go-up   go-down


95. del Boz J, García JM, Martínez S, Gómez M: Giant melanoma and depression. Am J Clin Dermatol; 2009;10(6):419-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant melanoma and depression.
  • A 29-year-old female patient presented with a giant melanoma on the external side of the left arm and concomitant multiple visceral metastases.
  • The patient also had major depression and had avoided a consultation despite the large size of the lesion, delaying the diagnosis and treatment of her melanoma, which as far as we know is the largest, primary cutaneous melanoma ever reported.
  • [MeSH-major] Depressive Disorder / complications. Melanoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824743.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


96. Inoue T, Kobayashi K, Sawada M, Ishizaki S, Ito H, Fujibayashi M, Tanaka M: Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma. Dermatol Res Pract; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma.
  • A 79-year-old Japanese woman presented with a 3-year history of brown-black macule on her right upper arm without symptom.
  • We suspected pigmented skin lesions including seborrheic keratosis, pigmented eccrine poroma, and malignant melanoma and excised completely with a 5 mm margin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811602.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2929512
  •  go-up   go-down


97. Fairweather P, O'Rourke T, Strutton G: Rare complication of Q fever vaccination. Australas J Dermatol; 2005 May;46(2):124-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 32-year-old woman with a past history of malignant melanoma presented with a lump in the upper left arm that was excised.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Melanoma / diagnosis

  • Genetic Alliance. consumer health - Q fever.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842410.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Bacterial Vaccines
  •  go-up   go-down


98. Nieto L, Joseph G, Stella A, Henri P, Burlet-Schiltz O, Monsarrat B, Clottes E, Erard M: Differential effects of phosphorylation on DNA binding properties of N Oct-3 are dictated by protein/DNA complex structures. J Mol Biol; 2007 Jul 20;370(4):687-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • N Oct-3, a transcription factor member of the POU protein family, is implicated in normal central nervous system development but also in melanoma growth.
  • Having observed that both the PORE and NORE DNA-association modes depend on a strong anchoring of the POUh subdomain rigid arm into the DNA-target minor groove, in contrast to the MORE mode, we have formulated the hypothesis that phosphorylation of the conserved Ser101 residue located in the N Oct-3 POUh arm could lead to differential results in DNA binding according to the type of target.
  • Here we demonstrate that, in vitro, Ser101 is phosphorylated by protein kinase A (PKA), either purified or contained in melanoma (624 mel) nuclear extract, and that this phosphorylation indeed significantly reduced N Oct-3 DBD binding to PORE and NORE motifs, most likely by hampering the POUh rigid arm insertion in the DNA minor groove.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543985.001).
  • [ISSN] 0022-2836
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Extracts; 0 / Octamer Transcription Factor-3; 0 / POU Domain Factors; 17885-08-4 / Phosphoserine; 9007-49-2 / DNA; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


99. Minamiya Y, Ogawa J: The current status of sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2005 Apr;11(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sentinel lymph node (SLN) mapping has become a common procedure in the treatment of breast cancer and malignant melanoma.
  • Nevertheless, SLN mapping is not widely used in the treatment of NSCLC for several reasons: first, special precautions are required to minimize exposure when radioisotopes are used as tracers; second, it is difficult to detect the blue dyes used as tracers within anthoracotic thoracic lymph nodes; and third, major complications comparable to the arm edema seen in breast cancer or the lymphedema and nerve injury seen in melanoma are not seen with mediastinal lymph node dissection (MLND).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Isosulfan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900235.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue
  • [Number-of-references] 34
  •  go-up   go-down


100. Thompson JF, Hodi FS, Zembowicz A: Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med; 2007 Jan 18;356(3):285-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229956.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down






Advertisement